

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 25/00, 43/04, A61K 49/04	A1	(11) International Publication Number: WO 99/12416
		(43) International Publication Date: 18 March 1999 (18.03.99)
<p>(21) International Application Number: PCT/US98/18750</p> <p>(22) International Filing Date: 9 September 1998 (09.09.98)</p> <p>(30) Priority Data: 60/058,260 9 September 1997 (09.09.97) US</p> <p>(71) Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).</p> <p>(72) Inventors: WANG, Denong; Apartment 34, 238 Fort Wash- ington Avenue, New York, NY 10032 (US). ERLANGER, Bernard, F.; 163-16 15th Drive, Whitestone, NY 11357 (US). KABAT, Elvin, A.; Apartment 34, 238 Fort Wash- ington Avenue, New York, NY 10032 (US).</p> <p>(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).</p>		<p>(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
(54) Title: T-INDEPENDENT CONJUGATE-VACCINES		
<p>(57) Abstract</p> <p>This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) $\alpha(1,6)$dextran can elicit a markedly enhanced IgA response in T-cell free mice (20-50 fold higher than in normal mice); 2) co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen; and 3) a dextran-Gag conjugate can elicit the Gag-specific IgA. Thus, the invention identified $\alpha(1,6)$dextran as a carrier molecule for producing the T-independent conjugates and as an adjuvant for the enhancement of IgA production. The T-independent property of these conjugates makes it especially useful in vaccinations against HIV and other infectious and non-infectious diseases associated with T-cell deficiency.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

T-Independent Conjugate-Vaccines

5 This application claims the benefit of U.S. provisional application No. 60/058,260, filed September 9, 1997, the contents of which is hereby incorporated by reference.

10 Throughout this application, various references are referred to with arabic numbers. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this specification, preceding the claims.

15 Background of the Invention

20 Recognition of polysaccharides as antigens began with the study in 1917 by Dochez and Avery(1) who found that when *pneumococci* are grown in fluid media, there is a substance in the culture fluid which precipitated specifically with antisera to the same *pneumococcus*. Heidelberger and Avery(2) showed that this substance was polysaccharide and not protein as thought previously.

25 Microbial polysaccharides as antigens gained renewed interest when it was found that strains of microorganisms resistant to antibiotics and/or chemotherapeutic agents appeared increasingly and became a worldwide problem. Vaccines with microbial polysaccharides were developed to
30 meet the requirements.

Given the feature of host immune responses induced by polysaccharides, they were classified as the
35 "T-independent"(TI) antigen. The concept of T-independency arose from the observations that neonatally thymectomized (3,4) and nude mice(5) gave unimpaired

-2-

antibody responses to large polymeric molecules, although they were not able to mount a humoral response to T-dependent (TD) antigens, such as proteins. They are further divided into type I (TI-I) and type II (TI-II), based on the ability to elicit antibodies in the CBA/N mouse strain, with an X-chromosome linked immunodeficiency (xid) (6). Lipopolysaccharides (LPS) of gram-negative bacteria which induce antibodies in such strains are TI-I antigens; capsular polysaccharides of gram positive bacteria and exopolysaccharides, induced no response in xid strains, are TI-II antigens.

T-dependent and T-independent antigens may induce different pathways of B cell activation and differentiation, germinal center reactions and antibody-secreting cell responses. T-dependent antigens can induce germinal center formation as well as the antibody-secreting cell responses. In germinal centers, B cells may undergo somatic hypermutation, IgH class-switching and memory cell induction (7-9). These molecular events are believed to be T cell dependent. In contrast to the T-dependent patterns of B cell activation which are associated with germinal center development, many T-independent antigens, such as the TI-I antigen LPS and the TI-II antigens, polyvinylpyrrolidone and DNP-Ficoll, are reported to induce only minimal or no germinal center development (72).

The onset of full response to polysaccharide TI-II antigens in both mice and humans is strikingly delayed. In mice (10) antibody responses to TI-I antigens (LPS and other) and protein antigens reach adult levels within 1-2 weeks; antibodies to TI-II antigens can be detected only at 2-3 weeks. For pneumococcal polysaccharides SSS-III and dextran B1355S, full development of the antibody response is not reached until 4 weeks; with levan and $\alpha(1,6)$ dextran,

-3-

7 and 13 weeks respectively, are needed. In humans, children younger than 18 months of age fail to respond to microbial polysaccharides or produce antibodies at levels too low to be protective. Such poor responsiveness generally lasts until 5 years of age. Thus, there is a period when maternal-derived protective antibodies have declined, yet the age-related development of immunity to bacterial infection remains immature. Pathogens causing severe problems during this high-risk period have long posed the need for developing efficient vaccines.

Thus, the "T-independent " property of polysaccharide antigens has been considered as a limitation to their application for vaccination. In 1990, Robbins and Schneerson introduced a conjugate strategy for vaccine development(11). By coupling purified capsular polysaccharides of *Haemophilus influenzae* B with tetanus toxoid, the first polysaccharide-protein conjugate against this bacterium was made(12). Instead of large capsular polysaccharides, its oligosaccharide was conjugated with different protein carriers for vaccinations (13,14), so that the conjugate-vaccines preserve the antigenic specificities of the original polysaccharides but gain the T-dependent property in addition. A significant shift in the age at which the anti-carbohydrate response can be induced and Ig class switches to the protective IgG isotypes were observed with these vaccines, resulting in better protection of high-risk populations from *Haemophilus influenzae* B. The principles underlying the approaches to *Haemophilus influenzae* B vaccines, have been extended to microbial polysaccharides of other bacteria, viruses and parasites, etc.(15).

The magnitude of the worldwide AIDS epidemic presents current challenges for developing effective vaccines and

-4-

therapeutic strategies. These efforts are hampered, however, by the targeted elimination of T-cells by the retrovirus(16, 17), by difficulties in inducing effective neutralizing antibodies to HIV1(7-19), and by the lack of an effective strategy for the induction of mucosal immune response, which may eliminate the invasion on the mucosal surface before a systemic infection occurs. The center of the difficulties in developing HIV-vaccines is a paradox caused by the retrovirus: effective vaccinations require the functions of T-cell which are however destroyed directly by the virus.

An effective vaccination against HIV must fulfill the following requirements: 1) It must elicit an effective immune response to HIV in the presence and absence of functional T-cells; 2) It can induce anti-HIV antibody of the IgA isotype to enhance the mucosal protection; and 3) It is safe, non-toxic and clinically acceptable. In addition, a vaccination strategy applying such T-independent Vaccines must be able to inherit all the advantages of the current T-dependent "conjugate-vaccines".

Our invention described here provides the concept, materials and the methodology for the development of such vaccination strategies against HIV, and other infectious agents.

Summary of the Invention

This invention includes the conception of the T-independent conjugate-vaccines, their application in the induction of antigen specific IgA and in reshaping the repertoire of responding B-cells. We demonstrated for the first time that a specific polysaccharide antigen $\alpha(1,6)$ dextran can elicit a markedly enhanced IgA response in T-cell free

-5-

5 mice; co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen; and its conjugates with the Gag protein of HIV-1 can elicit Gag-specific IgA in the presence and absence of functional T-cells.

10 The invention identified and illustrated specifically: 1. $\alpha(1,6)$ dextran can serve as a carrier molecule for producing the T-independent conjugate-vaccines; 2. The polysaccharide can serve as an adjuvant to enhance IgA production for other specificities and to reshape the repertoire of responding B-cells; 3. The technical details for producing the first generation of the TI-conjugate-vaccines and their
15 *in vitro* identification are described; and 4. A combinatory vaccination strategy, incorporating the advantage of both "TD-conjugate" and our "TI- conjugates", is proposed and experimentally illustrated.

20 The T-independent property of these conjugates makes it especially useful in vaccinations against HIV, AIDS-associated opportunistic infections, and other infectious- and non-infectious diseases with T-cell deficiency (including tumors). Its application is, however, not restricted in the T-cell deficient situation.

25

Dkt. 54275-A-PCT/JPW/EMW

What is claimed is:

30 This invention provides a method of identifying an $\alpha(1,6)$ dextran molecule as a potent IgA-B cell activator comprising the steps of:

- 35 (a) conjugating a first and a second $\alpha(1,6)$ dextran molecule, each molecule having a different molecular weight of ≥ 90 kd, to an HIV-1 gp120 glycoprotein, an HIV-1 protein or epitopes thereof to produce a T-independent $\alpha(1,6)$ dextran

-6-

conjugate;

- 5 (b) administering the first T-independent $\alpha(1,6)$ dextran conjugate produced in step (a) to a subject to induce anti-HIV-1 gp120 antibodies in the subject;
- (c) detecting an amount of anti-HIV-1 gp120 antibodies induced in step (b) in the subject;
- 10 (d) administering the second T-independent $\alpha(1,6)$ dextran conjugate produced in step (a) to a subject to induce anti-HIV-1 gp120 antibodies in the subject;
- (e) detecting an amount of anti-HIV-1 gp120 antibodies induced in step (d) in the subject;
- 15 (f) comparing the amount of anti-HIV-1 gp120 antibodies detected in step (c) to the amount of anti-HIV-1 gp120 antibodies detected in step (e), wherein detection of a greater amount of anti-HIV-1 gp120 antibodies induced by the first or second $\alpha(1,6)$ dextran molecule identifies the
- 20 $\alpha(1,6)$ dextran molecule which is a potent IgA-B cell activator.

25 In an embodiment of the above-described method, the induced anti-HIV-1 gp120 antibodies are IgA antibodies or IgG antibodies.

30 In another embodiment of the method, the HIV-1 gp120 glycoprotein is a deglycosylated wildtype HIV-1 gp120 glycoprotein or a deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein.

35 In a further embodiment of the method, the deglycosylated wildtype HIV-1 gp120 glycoprotein or the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein binds CD4 or an HIV-1 co-receptor.

In a further embodiment of the method the HIV-1 co-receptor

-7-

is HIV-1 coreceptor CCR5 or CXCR4.

5 In a further embodiment of the method, the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein has domains v_1 and v_2 deleted from the deglycosylated wildtype HIV-1 gp120 glycoprotein.

10 In a further embodiment of the above-described method, in step (a) the $\alpha(1,6)$ dextran molecule is conjugated to the HIV-1 gp120 glycoprotein or an epitope thereof, by a heteroligation technique.

15 In a further embodiment of the above-described method, the HIV-1 gp120 protein epitope is a carbohydrate epitope.

In a further embodiment of the method, the carbohydrate epitope is coupled to a lipid carrier and incorporated into the surface of a liposome carrier.

20 In a further embodiment of the method, an additional carbohydrate epitope is incorporated into the liposome, wherein the carbohydrate epitope comprises an isomaltosyl oligosaccharide.

25 In a further embodiment of the method, the isomaltosyl oligosaccharide comprises a $[\text{Glc}(\alpha(1,6))]_n$ motif.

30 In a further embodiment of the method, the HIV-1 gp120 protein or an epitope thereof is biotinylated and is conjugated to the $\alpha(1,6)$ dextran which is biotinylated by avidin.

35 In a further embodiment of the method, the HIV-1 gp120 glycoprotein epitope is Tn (GalNAc-Ser/Thr), Lewis Y ($\text{Fuc}\alpha 1 \rightarrow 2\text{Gal}\beta 1 \rightarrow 4 (\text{Fuc}\alpha 1 \rightarrow 3)\text{GlcNAc}\beta 1 \rightarrow 3\text{Gal}\beta 1 \rightarrow 4\text{Glc}\beta 1 \rightarrow \text{R}$) or peptide mimics thereof.

-8-

In a further embodiment of the method, the HIV-1 gp120 protein is a Gag p55 polyprotein or a capsid p24 protein.

5 In a further embodiment of the method, the Gag is a Gag-GST fusion protein or a purified Gag protein.

10 This invention also provides a method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 gp120 protein, comprising administering an effective amount of a T-independent $\alpha(1,6)$ dextran conjugate to the immunocompromised subject.

15 In another embodiment of the above-described method, the antibodies are IgA antibodies or IgG antibodies.

20 In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate comprises an $\alpha(1,6)$ dextran and a protein coupled thereto.

25 In a further embodiment of the method, the protein is HIV-1 gp120 glycoprotein, deglycosylated wildtype HIV-1 gp120 glycoprotein or the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein.

30 In a further embodiment of the method, the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein has domains v_1 and v_2 deleted from the deglycosylated wildtype HIV-1 gp120 glycoprotein.

35 In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate comprises gp120, a deletion form of gp120 wildtype, a deglycosylated gp120 or a deletion form of deglycosylated gp120.

In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate is DEX-LeY-peptide.

-9-

In a further embodiment of the method, the epitope of gp120 glycoprotein is a carbohydrate molecule.

5 In a further embodiment of the method, the carbohydrate molecule is Tn (GalNAc-Ser/Thr).

10 In a further embodiment of the method, the carbohydrate molecule is a peptide mimic of a mucin-type structure or of a peripheral poly-N-acetyl-glucosamine carbohydrate structure.

15 In a further embodiment of the method, the carbohydrate mimicking peptide is YPY that mimics mannose or WRY that mimics ($\alpha(1 \rightarrow 4)$ glucose).

In a further embodiment of the method, the carbohydrate molecule is Lewis Y ($\text{Fuc}\alpha 1 \rightarrow 2\text{Gal}\beta 1 \rightarrow 4 (\text{Fuc}\alpha 1 \rightarrow 3)\text{GlcNAc}\beta 1 \rightarrow 3\text{Gal}\beta 1 \rightarrow 4\text{Glc}\beta 1 \rightarrow \text{R}$).

20 In a further embodiment of the method, the epitope is a peptide mimic of Lewis Y.

25 In a further embodiment of the method, the peptide mimic of Lewis Y comprises the amino acid sequence YYRYD or YYRYDK.

30 In a further embodiment of the method, the induced antigen specific antibodies are IgA antibodies or IgG antibodies in the circulation of the subject or at mucosal sites of the subject.

In a further embodiment of the method, the induced mucosal IgA antibodies are colo-rectal, genital, or oral IgA antibodies.

35 In a further embodiment of the method, the immunocompromised subject is infected with human immunodeficiency virus-1 (HIV-1).

-10-

In a further embodiment of the method, the subject is T-cell deficient.

5 In a further embodiment of the method, the subject is not T-cell deficient.

10 In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate is administered to a mucosal surface of the immunocompromised subject or via a systemic route of vaccination.

15 In a further embodiment of the method, the administration is topical, oral, nasal, anal, liposome-mediated delivery, aerosol delivery, intravenous delivery or subcutaneous delivery.

20 This invention also provides a method of enhancing IgA response in an immunocompromised subject comprising administering $\alpha(1,6)$ dextran having a molecular weight of < 90kd and an effective amount of an antigen concurrently.

In a further embodiment of the method, the subject is T-cell deficient.

25 In a further embodiment of the method, the subject is not T-cell deficient.

30 In a further embodiment of the method, the antigen comprises an HIV-1 gp120 glycoprotein, or other HIV-1 proteins or epitopes derived from HIV proteins.

In a further embodiment of the method, the HIV-1 gp120 glycoprotein is deglycosylated wildtypeD gp120 protein.

35 In a further embodiment of the method, the deglycosylated wildtype HIV-1 gp120 glycoprotein is a deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein having

-11-

deletions of domains v_1 and v_2 .

5 In a further embodiment of the method, the HIV-1 gp120 glycoprotein epitope is Tn (GalNAc-Ser/Thr), Lewis Y (Fuc α 1 \rightarrow 2Gal β 1 \rightarrow 4 (Fuc α 1 \rightarrow 3)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc β 1 \rightarrow R) or peptide mimics thereof.

10 This invention also provides a method of treating an immunocompromised subject comprising the method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 gp120 protein, comprising administering an effective amount of a T-independent α (1,6)dextran conjugate to the immunocompromised subject.

15 This invention also provides a method of treating an immunocompromised subject comprising a method of enhancing IgA response in an immunocompromised subject comprising administering α (1,6)dextran having a molecular weight of < 90kd and an effective amount of an antigen concurrently.

20 This invention also provides a method of preventing AIDS or HIV-1 infection in a subject comprising the method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 gp120 protein, comprising administering an effective amount of a T-independent α (1,6)dextran conjugate to the immunocompromised subject.

25 This invention also provides a method of preventing AIDS or HIV-1 infection in a subject comprising a method of enhancing IgA response in an immunocompromised subject comprising administering α (1,6)dextran having a molecular weight of < 90kd and an effective amount of an antigen concurrently.

35

-12-

This invention also provides a method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran.

5 In another embodiment of the above-described methods, the microbes are Cytomegalovirus, Mycobacterium avium, or Cryptococcus.

10 In a further embodiment of the method, the microbial protein antigen or an epitope thereof is conjugated to $\alpha(1,6)$ dextran by a heteroligation technique.

15 This invention also provides a method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial protein, carbohydrate or a fragment thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by a method of producing a T-independent conjugate comprising
20 conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran to the subject.

25 This invention also provides a method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope thereof comprising administering $\alpha(1,6)$ dextran and an effective amount of an antigen sequentially or concurrently.

In an embodiment of either of the above-described methods wherein the subject is T-cell deficient.

30 The method of either of the above-described methods of inducing antigen specific IgA wherein the subject is not T-cell deficient.

35 This invention further provides a method of treating a microbial infection in a subject comprising the method inducing antigen specific IgA in a subject, wherein the

-13-

antigen is a bacterial envelope protein or a fragment thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by a method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran to the subject.

The method of any of the above described methods of inducing antigen specific IgA in a subject, wherein the microbial infection is an opportunistic infection.

In a further embodiment of the above described method, the subject is infected with HIV-1 or has AIDS.

This invention also provides a method of treating a microbial infection in a subject comprising the method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope thereof comprising administering $\alpha(1,6)$ dextran and an effective amount of an antigen sequentially or concurrently.

This invention further provides a method of preventing a microbial infection in a subject comprising the method of inducing antigen specific IgA in a subject, wherein the antigen is a bacterial envelope protein or a fragment thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by a method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran to the subject.

This invention further provides a method of preventing a microbial infection in a subject comprising the method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope thereof comprising administering $\alpha(1,6)$ dextran and an effective amount of an antigen sequentially or concurrently.

-14-

The method of of any the above described methods the T-independent $\alpha(1,6)$ dextran conjugate is administered to a mucosal surface of the microbial infected subject or via a systemic route of vaccination.

5

The method of any the above described methods the administration is topical, oral, nasal, anal, liposome-mediated delivery, aerosol delivery, intravenous delivery or subcutaneous delivery.

10

This invention also provides a composition comprising a T-independent conjugate in an amount effective to induce antigen specific IgA in a subject and a pharmaceutically acceptable carrier.

15

This invention also provides a method of producing a composition comprising a T-independent conjugate in an amount effective to induce antigen specific IgA in a subject and a pharmaceutically acceptable carrier comprising the method of claim 1 and further comprising admixing the T-independent conjugate and the pharmaceutically acceptable carrier.

20

A composition comprising an effective amount of a T-independent conjugate and a pharmaceutically acceptable carrier, wherein the T-independent conjugate is produced by the method of claim 1.

25

A composition comprising a effective amount of a T-independent conjugate and a pharmaceutically acceptable carrier, wherein the T-independent conjugate is produced by the method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran.

30

35

This invention also provides the use of the $\alpha(1,6)$ dextran molecule identified as a potent antibody activator in claim

-15-

1 as a carrier or an adjuvant for vaccines to enhance mucosal immunity.

- 5 67. The method of claim 1, wherein the T-independent conjugate is used as a vaccine to induce antigen specific IgA.

Brief Description of the Figures

5 Fig. 1: Demonstrates the first time the strikingly enhanced IgA response to $\alpha(1,6)$ dextran by a strain of T-cell free mice, C57BL(TCR b/d genes knock-out), which has been back-crossed to the C57BL background. TCR b/d KO mice and C57BL controls were both immunized i.v. with 10mg of $\alpha(1,6)$ dextran, N279, and at the indicated times spleen cells were isolated and the number of antigen specific ASC was determined by antigen-specific ELISA-spot assay. The specificity of ELISA-spots was established by competitive blocking with $\alpha(1,6)$ dextran, N279, but not by $\alpha(1,3)\alpha(1,6)$ dextran, B1355S. Six to ten animals were tested at each time point. ASC stands for antibody secreting cell. Data were expressed as the number of N279 specific ASC per 10^6 splenocytes. IgA response to $\alpha(1,6)$ dextran is enhanced in a strain of T-cell free mice of C57Bl background. this is consistent with our previous observation in the KO mice of mix background (129XC57BL/6J). TCR β/δ KO mice and C57BL controls were both immunized i.v. with 10 μ g of $\alpha(1-6)$ dextran, N279, and at the indicated times spleen cells were isolated and the number of antigen specific ELISA-spot assay. The specificity of ELISA-spots was established by competitive blocking with $\alpha(1-6)$ dextran, N279, but not by $\alpha(1-3)\alpha(1-6)$ dextran, B1355S. Six to ten animals were tested at each time point. Data are expressed as the number of N279 specific ASC per 10^6 splenocytes.

30 Fig. 2: Co-stimulation with $\alpha(1,6)$ dextran, the B1355S-specific IgA response was extensively enhanced in the KO mice. The KO mice and C57BL normal controls were immunized by i.v. injection of 10 mg polysaccharide B1355S each mouse or with 10 mg each of B1355S and $\alpha(1,6)$ dextran (Mix-Ags). At day 5 post-immunization, antigen-specific

35

-17-

ELISAspot assay were performed as described above (Legend for Fig. 1). In contrast to $\alpha(1,6)$ dextran, B1355S alone is not able to elicit Ig A response in both KO and normal C57BL mice. Co-injection with $\alpha(1,6)$ dextran, however, led to the induction of significant amount of IgA-ASCs specific for B1355S in KO mice and to much less extent in C57BL. In the same experiment, we applied $\alpha(1-3)\alpha(1-6)$ dextran (B1355S). By contrast, this polysaccharide (B1355S) was not able to elicit antigen specific IgA in both KO and normal C57BL mice (Fig. 2 Top portion). Thus, $\alpha(1-6)$ dextran, but not $\alpha(1-3)\alpha(1-6)$ dextran, can induce T-independent IgA responses, emphasizing the importance of the structural properties of stimulating antigen in the induction of IgA. As described above, the two polysaccharides differ only in their glycosidic linkage composition, providing us with important clues for identifying the structural characteristics critical for IgA induction (Aim 1).

Fig. 3: Co-immunization with $\alpha(1,6)$ dextran, the B1355S-specific B-cell response switched to κ light Chain predominant, resulting in an extended repertoire of responding B-cells in both T-cell free mice (KO, C57BL, TCR β/δ) and normal mice (C57BL). In response to the B1355S stimulation, both KO and normal mice produced dominantly antibodies of λ L-chain; this profile was however inverted to κ light Chain predominant, by the co-stimulator, $\alpha(1,6)$ dextran. Our previous studies showed that antibodies to $\alpha(1,6)$ dextran have no or very limited cross-reactivity to B1355S. The two microbial polysaccharides are structurally distinct, see ref.²² for a review. Thus, these data demonstrated that $\alpha(1,6)$ dextran can modulate the isotype profile and the repertoire of the responding B-cell to a given antigen.

-18-

Fig. 4: Boosting or primary immunization using the GAD conjugate modulate the isotype profile of responding B-cells: enhancement of IgA and k L-chain isotype. GK: Gag-KLH conjugate; GAD: Gag-dextran conjugate; KO: C57BL(TCR β / δ Knock-out) This figure summarized two separate experiments applying GAD conjugate, which is composed of the Gag polyprotein of HIV-1 and α (1,6)dextran. Different immunization strategies were applied. In the groups of GK/BALB and GAD /BALB, Balb/c mice were immunized by i.v. injection of purified 100mg of Gag-GST fusion protein mixed with FCA, two weeks late, injected (i.p.) with 50 mg of Gag-KLH conjugate mixed with IFA; at the fourth week, the GK/BALB group were boosted with 12.5 mg of Gag-KLH and the GAD/BALB group with 10mg GAD conjugate by i.v. injection. The remaining two groups were immunized by only one i.v. injection of 10mg GAD conjugate. At the 5th day after the last boosting or the primary immunization, the antigen-specific ELISAspot assays were performed to detect the number of ASC specific for the Gag protein and for the carrier, α (1,6)dextran.

Detailed Description Of The Invention

Dkt. 54275-A-PCT/JPW/EMW

What is claimed is:

1. This invention provides a method of identifying an α (1,6) dextran molecule as a potent IgA-B cell activator comprising the steps of:
 - (a) conjugating a first and a second α (1,6) dextran molecule, each molecule having a different molecular weight of ≥ 90 kd, to an HIV-1 gp120 glycoprotein, an HIV-1 protein or epitopes thereof to produce a T-independent α (1,6) dextran conjugate;
 - (b) administering the first T-independent α (1,6)

-19-

dextran conjugate produced in step (a) to a subject to induce anti-HIV-1 gp120 antibodies in the subject;

- 5 (c) detecting an amount of anti-HIV-1 gp120 antibodies induced in step (b) in the subject;
- (d) administering the second T-independent $\alpha(1,6)$ dextran conjugate produced in step (a) to a subject to induce anti-HIV-1 gp120 antibodies in the subject;
- 10 (e) detecting an amount of anti-HIV-1 gp120 antibodies induced in step (d) in the subject;
- (f) comparing the amount of anti-HIV-1 gp120 antibodies detected in step (c) to the amount of anti-HIV-1 gp120 antibodies detected in step (e),
- 15 wherein detection of a greater amount of anti-HIV-1 gp120 antibodies induced by the first or second $\alpha(1,6)$ dextran molecule identifies the $\alpha(1,6)$ dextran molecule which is a potent IgA-B cell activator.

20

2. In an embodiment of the above-described method, the induced anti-HIV-1 gp120 antibodies are IgA antibodies or IgG antibodies.

25

3. In another embodiment of the method, the HIV-1 gp120 glycoprotein is a deglycosylated wildtype HIV-1 gp120 glycoprotein or a deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein.

30

4. In a further embodiment of the method, the deglycosylated wildtype HIV-1 gp120 glycoprotein or the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein binds CD4 or an HIV-1 co-receptor.

35

5. In a further embodiment of the method the HIV-1 co-receptor is HIV-1 coreceptor CCR5 or CXCR4.

6. In a further embodiment of the method, the deletion

-20-

form of the deglycosylated wildtype HIV-1 gp120 glycoprotein has domains v_1 and v_2 deleted from the deglycosylated wildtype HIV-1 gp120 glycoprotein.

- 5 7. In a further embodiment of the above-described method, in step (a) the $\alpha(1,6)$ dextran molecule is conjugated to the HIV-1 gp120 glycoprotein or an epitope thereof, by a heterologation technique.
- 10 8. In a further embodiment of the above-described method, the HIV-1 gp120 protein epitope is a carbohydrate epitope.
- 15 9. In a further embodiment of the method, the carbohydrate epitope is coupled to a lipid carrier and incorporated into the surface of a liposome carrier.
- 20 10. In a further embodiment of the method, an additional carbohydrate epitope is incorporated into the liposome, wherein the carbohydrate epitope comprises an isomaltosyl oligosaccharide.
- 25 11. In a further embodiment of the method, the isomaltosyl oligosaccharide comprises a $[\text{Glc}(\alpha(1,6))]_n$ motif.
- 30 12. In a further embodiment of the method, the HIV-1 gp120 protein or an epitope thereof is biotinylated and is conjugated to the $\alpha(1,6)$ dextran which is biotinylated by avidin.
- 35 13. In a further embodiment of the method, the HIV-1 gp120 glycoprotein epitope is Tn (GalNAc-Ser/Thr), Lewis Y ($\text{Fuc}\alpha 1 \rightarrow 2\text{Gal}\beta 1 \rightarrow 4 (\text{Fuc}\alpha 1 \rightarrow 3)\text{GlcNAc}\beta 1 \rightarrow 3\text{Gal}\beta 1 \rightarrow 4\text{Glc}\beta 1 \rightarrow \text{R}$) or peptide mimics thereof.
14. In a further embodiment of the method, the HIV-1 gp120

-21-

protein is a Gag p55 polyprotein or a capsid p24 protein.

5 15. In a further embodiment of the method, the Gag is a Gag-GST fusion protein or a purified Gag protein.

10 16. This invention also provides a method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 gp120 protein, comprising administering an effective amount of a T-independent $\alpha(1,6)$ dextran conjugate to the immunocompromised subject.

15 17. In another embodiment of the above-described method, the antibodies are IgA antibodies or IgG antibodies.

20 As defined herein an effective amount of a T-independent $\alpha(1,6)$ dextran conjugate is an amount of the conjugate that induces HIV-1 neutralization antibodies of IgA and/or IgG isotypes in the circulation of a subject and/or at mucosal sites of the body of the subject. HIV-1 neutralization antibodies are antibodies which specifically bind to the HIV neutralization epitopes such as the CD4-binding region
25 or those regions interacting with an HIV coreceptor, such as CCR5 so as to block infection by HIV-1.

30 18. In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate comprises an $\alpha(1,6)$ dextran and a protein coupled thereto.

35 19. In a further embodiment of the method, the protein is HIV-1 gp120 glycoprotein, deglycosylated wildtype HIV-1 gp120 glycoprotein or the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein.

20. In a further embodiment of the method, the deletion

-22-

form of the deglycosylated wildtype HIV-1 gp120 glycoprotein has domains v_1 and v_2 deleted from the deglycosylated wildtype HIV-1 gp120 glycoprotein.

- 5 21. In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate comprises gp120, a deletion form of gp120 wildtype, a deglycosylated gp120 or a deletion form of deglycosylated gp120.
- 10 22. In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate is DEX-LeY-peptide.
- 15 23. In a further embodiment of the method, the epitope of gp120 glycoprotein is a carbohydrate molecule.
24. In a further embodiment of the method, the carbohydrate molecule is Tn (GalNAc-Ser/Thr).
- 20 25. In a further embodiment of the method, the carbohydrate molecule is a peptide mimic of a mucin-type structure or of a peripheral poly-N-acetyl-glucosamine carbohydrate structure.
- 25 26. In a further embodiment of the method, the carbohydrate mimicking peptide is YPY that mimics mannose or WRY that mimics $(\alpha(1 \rightarrow 4)$ glucose.
- 30 26. In a further embodiment of the method, the carbohydrate molecule is Lewis Y ($\text{Fuc}\alpha 1 \rightarrow 2\text{Gal}\beta 1 \rightarrow 4$ ($\text{Fuc}\alpha 1 \rightarrow 3$) $\text{GlcNAc}\beta 1 \rightarrow 3\text{Gal}\beta 1 \rightarrow 4\text{Glc}\beta 1 \rightarrow \text{R}$).
27. In a further embodiment of the method, the epitope is a peptide mimic of Lewis Y.
- 35 28. In a further embodiment of the method, the peptide mimic of Lewis Y comprises the amino acid sequence

-23-

YYRYD or YYRYDK.

29. In a further embodiment of the method, the induced antigen specific antibodies are IgA antibodies or IgG antibodies in the circulation of the subject or at mucosal sites of the subject.
30. In a further embodiment of the method, the induced mucosal IgA antibodies are colo-rectal, genital, or oral IgA antibodies.
31. In a further embodiment of the method, the immunocompromised subject is infected with human immunodeficiency virus-1 (HIV-1).
32. In a further embodiment of the method, the subject is T-cell deficient.
- As used herein T cell deficiency is defined as CD4 counts of between 200 and 500 cells/mm³ or lower than 200 cells/mm³.
33. In a further embodiment of the method, the subject is not T-cell deficient.
34. In a further embodiment of the method, the T-independent $\alpha(1,6)$ dextran conjugate is administered to a mucosal surface of the immunocompromised subject or via a systemic route of vaccination.
35. In a further embodiment of the method, the administration is topical, oral, nasal, anal, liposome-mediated delivery, aerosol delivery, intravenous delivery or subcutaneous delivery.
36. This invention also provides a method of enhancing IgA response in an immunocompromised subject comprising administering $\alpha(1,6)$ dextran having a molecular weight

-24-

of < 90kd and an effective amount of an antigen concurrently.

5 37. In a further embodiment of the method, the subject is T-cell deficient.

38. In a further embodiment of the method, the subject is not T-cell deficient.

10 In a further embodiment of the method, the antigen comprises an HIV-1 gp120 glycoprotein, or other HIV-1 proteins or epitopes derived from HIV proteins.

15 In a further embodiment of the method, the HIV-1 gp120 glycoprotein is deglycosylated wildtypeD gp120 protein.

20 41. In a further embodiment of the method, the deglycosylated wildtype HIV-1 gp120 glycoprotein is a deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein having deletions of domains v_1 and v_2 .

25 42. In a further embodiment of the method, the HIV-1 gp120 glycoprotein epitope is Tn (GalNAc-Ser/Thr), Lewis Y (Fuc α 1 \rightarrow 2Gal β 1 \rightarrow 4 (Fuc α 1 \rightarrow 3)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc β 1 \rightarrow R) or peptide mimics thereof.

30 43. This invention also provides a method of treating an immunocompromised subject comprising the method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 gp120 protein, comprising administering an effective amount of a T-independent α (1,6)dextran conjugate to the immunocompromised subject.

35

44. This invention also provides a method of treating an

-25-

immunocompromised subject comprising a method of enhancing IgA response in an immunocompromised subject comprising administering $\alpha(1,6)$ dextran having a molecular weight of $< 90\text{kd}$ and an effective amount of an antigen concurrently.

45. This invention also provides a method of preventing AIDS or HIV-1 infection in a subject comprising the method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 gp120 protein, comprising administering an effective amount of a T-independent $\alpha(1,6)$ dextran conjugate to the immunocompromised subject.

46. This invention also provides a method of preventing AIDS or HIV-1 infection in a subject comprising a method of enhancing IgA response in an immunocompromised subject comprising administering $\alpha(1,6)$ dextran having a molecular weight of $< 90\text{kd}$ and an effective amount of an antigen concurrently.

47. This invention also provides a method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran.

As used herein microbial antigen proteins or epitopes thereof include bacterial and viral proteins, carbohydrate molecules, and epitopes thereof. Microbial antigens include but are not limited to Cytomegalovirus, Mycobacterium avium, and Cryptococcus. One of ordinary skill in the art will be readily familiar with numerous additional bacteria and viruses whose proteins, polysaccharides, and epitopes thereof may be used in the above-described methods.

48. In another embodiment of the above-described methods,

-26-

the microbes are Cytomegalovirus, Mycobacterium avium, or Cryptococcus.

- 5 49. In a further embodiment of the method, the microbial protein antigen or an epitope thereof is conjugated to $\alpha(1,6)$ dextran by a heterologation technique.
- 10 50. This invention also provides a method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial protein, carbohydrate or a fragment thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by a method of producing a T-independent conjugate comprising conjugating a
- 15 microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran to the subject.
- 20 51. This invention also provides a method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope thereof comprising administering $\alpha(1,6)$ dextran and an effective amount of an antigen sequentially or concurrently.
- 25 52. In an embodiment of either of the above-described methods wherein the subject is T-cell deficient.
- 30 53. The method of either of the above-described methods of inducing antigen specific IgA wherein the subject is not T-cell deficient.
- 35 54. This invention further provides a method of treating a microbial infection in a subject comprising the method inducing antigen specific IgA in a subject, wherein the antigen is a bacterial envelope protein or a fragment thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by a method of producing a

-27-

T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran to the subject.

- 5 55. The method of any of the above described methods of inducing antigen specific IgA in a subject, wherein the microbial infection is an opportunistic infection. **Examples of opportunistic infections include but are not limited to infections by Cytomegalovirus, Mycobacterium**
10 **avium, or Cryptococcus.**
56. In a further embodiment of the above described method, the subject is infected with HIV-1 or has AIDS.
- 15 57. This invention also provides a method of treating a microbial infection in a subject comprising the method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope thereof comprising administering $\alpha(1,6)$ dextran and an
20 effective amount of an antigen sequentially or concurrently.
- 25 58. This invention further provides a method of preventing a microbial infection in a subject comprising the method of inducing antigen specific IgA in a subject, wherein the antigen is a bacterial envelope protein or a fragment thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by a method of producing a
30 T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran to the subject.
- 35 59. This invention further provides a method of preventing a microbial infection in a subject comprising the method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope

-28-

thereof comprising administering $\alpha(1,6)$ dextran and an effective amount of an antigen sequentially or concurrently.

- 5 60. The method of any of claims 50, 51, 54, 56, 57, 58 and 58, wherein the T-independent $\alpha(1,6)$ dextran conjugate is administered to a mucosal surface of the microbial infected subject or via a systemic route of vaccination.
- 10 61. The method of any of claims 50, 51, 54, 56, 57, 58 and 59, wherein the administration is topical, oral, nasal, anal, liposome-mediated delivery, aerosol delivery, intravenous delivery or subcutaneous delivery.
- 15 62. This invention also provides a composition comprising a T-independent conjugate in an amount effective to induce antigen specific IgA in a subject and a pharmaceutically acceptable carrier.
- 20 63. This invention also provides a method of producing a composition comprising a T-independent conjugate in an amount effective to induce antigen specific IgA in a subject and a pharmaceutically acceptable carrier comprising the method of claim 1 and further comprising admixing the T-independent conjugate and the pharmaceutically acceptable carrier.
- 25 64. A composition comprising an effective amount of a T-independent conjugate and a pharmaceutically acceptable carrier, wherein the T-independent conjugate is produced by the method of claim 1.
- 30 65. A composition comprising an effective amount of a T-independent conjugate and a pharmaceutically acceptable carrier, wherein the T-independent
- 35

-29-

conjugate is produced by the method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran.

5

66. This invention also provides the use of the $\alpha(1,6)$ dextran molecule identified as a potent antibody activator in claim 1 as a carrier or an adjuvant for vaccines to enhance mucosal immunity.

10

67. The method of claim 1, wherein the T-independent conjugate is used as a vaccine to induce antigen specific IgA.

15

1) The concept of the T-independent conjugate-vaccines.

20

The T-independent property of microbial polysaccharides has been well-documented²² and was briefly described in the background section. The successful application of the "T-dependent conjugate-vaccines" for more than a decade has strongly influenced the direction of the field of vaccine development in such a way that certain advantages of the T-independent antigen and their potential applications have been almost completely ignored. These include application in the field of HIV vaccination. Our finding that a classical TI-II antigen, $\alpha(1,6)$ dextran can elicit a strikingly enhanced IgA response in the absence of T-cells (Fig.1) led to the thoughts of an alternative direction, i.e., the development of the "T-independent conjugate-vaccines".

30

By definition, the T-independent conjugate-vaccines are newly generated molecules produced by coupling an antigenic determinant or an antigenic molecule to a T-independent carrier molecule, such as a polysaccharide. Such conjugates retain the given antigenic specificities

35

-30-

and also the property of the carrier molecule itself. They may be completely T-independent, such as a hapten-polysaccharide conjugate; or could be "semi-T-independent" as when a protein molecule is coupled to a polysaccharide. The latter may function like a T-independent antigen in the initial stimulation of immune cells but show the T-dependent reactivities after the protein is processed *in vivo*.

Our goal is to use the potential advantages of TI-antigens for the development of a vaccination strategy. These include their ability to work well in the absence of functional T-cells; and the unique properties of a particular carbohydrate molecule, which may determine its *in vivo* processing by host cells, cellular compartment localization and its interacting lymphocytes (see Ref. (22), for a recent review). The structural diversity of carbohydrate molecules, the polymorphism of microbial polysaccharides and of animal cell derived carbohydrate-containing molecules and the development of the synthetic polymer industry provide an un-limited resource for the application of our concept of the "T-independent conjugate-vaccines".

2) Identification of $\alpha(1,6)$ dextran as a carrier molecule for producing the "T-independent conjugate-vaccines" and as an adjuvant for IgA induction.

Antibody of IgA isotype plays important roles in mucosal immune response to foreign antigen. Induction of specific IgA to HIV proteins may eradicate the invaded virus on the mucosal surface at the local sites before the systemic infection occurs. Vaccines directed to IgA production are thus critical in preventing HIV infection. We identify here $\alpha(1,6)$ dextran as a suitable carrier for the production

-31-

of a class of T-independent conjugate-vaccines designed to elicit the antigen specific IgA response. In addition, $\alpha(1,6)$ dextran itself can serve as an adjuvant for enhancing IgA response.

5

Native dextran N279 is a near-linear macromolecule of glucose with 90% $\alpha(1-6)$, 5% $\alpha(1-)^1$ and 5% $\alpha(1-3)$ linkages, (24) derived from *Leuconostoc mesenteroides*, strain NRRL B512. The predominant $\alpha(1-6)$ glycosidic linkages make it uniquely flexible. Differing from other glycosidic bonds, three torsion (rotational) angles, ϕ , ψ and ω are required to define the conformation of an $\alpha(1-6)$ linkage. It is also very stable in vivo, since no mammalian enzyme can digest the linkage. After injection, the polysaccharide was found to be trapped and persist in the splenic follicles, leading to the formation of antigen specific germinal centers (25). In humans, $\alpha(1-6)$ dextran of relatively smaller molecular weight has been safely applied as blood expander for many years (26). Most importantly, we showed in this report that $\alpha(1,6)$ dextran can elicit a markedly enhanced IgA response in T-cell free mice (Fig.1); co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen (Fig.2); and a dextran-Gag conjugate can elicit the Gag-specific IgA (Fig. 4).

25

Data illustrated in Fig. 2 & 3 indicated an additional application of $\alpha(1-6)$ dextran, i.e., to apply it directly on a mucosal surface wherein an infection occurred and a specific antibody response were taking place. Introducing

30

¹ This symbol designates the attachment of a terminal nonreducing end sugar to an adjacent residue by $\alpha(1-6)$ linkage and other glucopyranosidic bonds²⁴

-32-

this non-toxic molecule locally may help to reshape the repertoire of responding cells and their H & L chain isotypes.

5 **3) A combinatorial vaccination strategy applying both TI- and TD conjugates.**

10 As illustrated in Fig.4, an immunization directed to the Gag polyprotein of HIV-1 was initiated by a T-dependent antigen and finally boosted using a semi-TI conjugate-vaccine, the GAD conjugate. The GK-group of mice, who were immunized by Gag-GST and boosted with Gag-KLH, specific IgG but not IgA was induced. Boosting with the GAD conjugate elicited both IgG and IgA. In
15 addition, the repertoire of the responding B-cells switched to kappa light chain predominance. These data demonstrated a vaccine strategy that combines the advantages of both TD and TI conjugate-vaccines.

20 In most AIDS patients, the antibody response to HIV protein was already initiated by the infection. Vaccination with the TI-conjugates alone may be sufficient to induce a protective response having antibodies of both IgG and IgA isotypes. Boosting with TI-conjugates can be an important
25 addition to all current HIV vaccination strategy. A TI-conjugate composed of $\alpha(1-6)$ dextran and the Env protein of HIV-1 or its functional epitopes shall be developed to meet the current needs.

30 **4) Methodology in producing the T-independent conjugate-vaccines**

A) **The GAD type of conjugates:** The GAD stands for Gag, Avidin and $\alpha(1,6)$ Dextran. The dextran molecule was coupled with Biotin-LC-Hydrazide (PIERCE, 21340X) and then linked
35 to a biotinylated protein by avidin. The use of

-33-

Biotin-LC-Hydrazide introduces an extended spacer arm between the molecules.

a. Oxidization of dextran to produce CHO groups.

5 $\alpha(1,6)$ dextran, preparation N279 (B512), was dissolved in
0.01M N_2 Acetate buffer, pH5.5, at 10mg/ml and warmed in
37°C water bath for 30 minutes. N_2IO_4 was then added to the
final concentration of 1×10^{-2} M. Mix the solution well and
let it stand at room temperature for one hour in dark.
10 Dialyze the preparation against 0.02M BBS (Borate buffered
saline) pH8., 4°C, overnight;

b. Coupling of Biotin-LC-Hydrazide to the oxidized dextran.

The above oxidized dextran was diluted 10 fold in
15 0.1 M N_2 Acetate pH5.5. A 1/3 volume of 5mM
Biotin-LC-Hydrazide was added drop wise. The mixture was
shaking at RT for one hour. The reaction was terminated by
addition of 0.5 ml of 1 M Tris HCL, pH7.5. The mixture
was then dialyzed against Tris buffer (0.1M Tris pH7.5,
20 0.1M NaCl, 2.0mM $MgCl_2$);

c. Coupling of NHS-Biotin(BRL #5533LA) to Gag. Standard
method was applied for the coupling reaction. The Gag
protein of HIV-1 was expressed as Gag-GST fusion protein in
25 *E. coli.* and purified by Glutathione-agarose beads (Sigma,
G4510) by the manufacture's standard protocol.

d. Link the two biotinylated molecules by avidin. The
biotinylated Gag, avidin and the biotinylated dextran were
30 mixed at the molar ratio of 20:4:1 and nutating at RT for
two hours. The conjugate was kept at 4°C before
application.

B) Glutaraldehyde-conjugation

35 Amino-dextran (Molecular Probes, D-7144, D-1861, D-7145)

-34-

were couple to Gag protein by Glutaraldehyde. Glutaraldehyde was added to the mixtures of Gag and amino-dextran to the final concentration of 0.2%. They were nutating at RT for two hours. The reaction was
5 stopped by addition of 1 M Ethanolamine at 6.1ml/ml. The mixture was nutated at RT for additional 2 hours and then dialyzed against 1XPBS, overnight.

10 C) An ELISA-based method for monitoring the quality of a conjugate

a. Coat ELISA plate with monoclonal anti-dextran, 45.21.1(a,k), at 5mg/ml, in 0.1M NaHCO_3 pH9.6, 37°C, 2 hours; Wash the plates using ELISA washing solution
15 in(1XPBS, 0.05% Tween20, 0.025% NaAzide) and blocked with the same solution containing 1%BSA;

b. Incubate the coated plates with serial dilution of the conjugate at 37 °C for 2 hours then wash them with ELISA
20 washing solution;

c. Incubate with antibodies specific for different epitopes of a given protein at 37°C for 2 hours then wash them with ELISA washing solution;

25 d. Incubate with a second antibody specific for the isotype of the anti-protein antibody used above to monitor the conjugated epitopes; in separate wells, apply an alkali phosphatase(AP)-labeled anti-dextran, such as 45.21.1-AP,
30 to detect the available epitopes of the carrier.

Our experience indicates that this method is valuable for monitor the quality of the TI-conjugates. Results correlate well with in vivo induction of the antibody
35 response by a conjugate.

References for the First Series of Experiments

1. Dochez, A.R. & Avery, O.T. *J. Exp. Med.* **26**, 477-493
5 (1917).
2. Heidelberger, M. & Avery, O.T. *J. Exp. Med.* **38**, 73-80
(1923).
- 10 3. Basten, A. & Howard, J.G. in *Contemporary Topics in Immunobiology* (ed. Davies, A.J.S.) 265 (Plenum, New York, 1973).
- 15 4. Humphrey, J.H., Parrott, D.M.V. & East, J. *Immunology* **7**, 419-439 (1964).
5. Weissman, I.L., Gutman, G.A., Friedberg, S.H. & Jerabek, L. *Adv. Exp. Med. Biol.* **66**, 229-237 (1976).
- 20 6. Scher, I. *Adv. Immunol.* **33**, 1-71 (1982).
7. Berek, C. & Ziegner, M. *Immunol.Today.* **14**, 400-404
(1993).
- 25 8. Kroese, F.G.M., Timens, W. & Nieuwenhuis, P. *Curr. Topics Path.* **84**, 103-148 (1990).
9. Kraal, G., Weissman, I.L. & Butcher, E.C. *Nature* **298**,
377-379 (1982).
- 30 10. Howard, J. in *Towards Better Carbohydrate Vaccines. Proceedings of a meeting organized by the World Health Organization, 9-11 October 1986, Geneva* (eds. Bell, R. & Torrigiani, G.) 221-229 (John Wiley & Sons,

-36-

Chichester New York Brisbane Toronto Singapore,
1987).

11. Robbins, J.B. & Schneerson, R. *J. Infct. Dis.* **161**,
821-832 (1990).

5

12. Schneerson, R., Barrera, O., Sutton, A. & Robbins,
J.B. *J. Exp. Med.* **152**, 361-376 (1980).

13. Madore, D.V., et al. *Pediatrics* **85**, 331-337 (1990).

10

14. Ahonkhai, V.I., et al. *Pediatrics* **85**, 676-681 (1990).

15. Schneerson, R., Robbins, J.B., Szu, S.C. & Yang, Y. in
*Towards better carbohydrate vaccines Proceedings of
a meeting organized by the World Health Organization,
9-11 October 1986, Geneva* (eds. Bell, R. &
Torrighiani, G.) 307-327 (John Wiley & Sons, Chichester
New York Brisbane Toronto Singapore, 1987).

15

16. Varmus, H.E. in *Mobile Genetic Elements* (ed. Shapiro,
J.A.) 411-501 (Academic Press, New York, 1983).

20

17. Sabin, A.B. *Proc. Natl. Acad. Sci. USA* **89**, 8852-8855
(1992).

25

18. Kohler, H., Goudsmit, J. & Nara, P. *J. Acq. Imm. Def.
Synd.* **5**, 1158-1168 (1992).

19. Nara, P.L., Garritty, R.R. & Goudsmit, J. *FASEB J.* **5**,
2437-2455 (1991).

30

20. Wang, D., Stall, A.M. & Kabat, E.A. in *The 9th
International Congress of Immunology* (ed. AAI) 515 (
San Francisco, California,, 1995).

-37-

21. Wang, D., et al. in *7th International Workshop of WACIID* (Ikoino Mura, Yamagata, Japan., 1995).
- 5 22. Wang, D. & Kabat, E.A. in *Structure of Antigens* (ed. Regenmortal, M.H.V.V.) 247-276 (CRC Press, Boca Raton New York London Tokyo, 1996., 1996).
23. BRIAND, J., et al. *Proc. Natl. Acad. Sci. USA In press* (1997).
- 10 24. Jeanes, A. *Mol. Immunol.* **23**, 999-1028 (1986).
25. Wang, D., Wells, S.M., Stall, A.M. & Kabat, E.A. *Proc. Natl. Acad. Sci. USA* **91**, 2504-2506 (1994).
- 15 26. Kabat, E.A. & Berg, D. *J. Immunol.* **70**, 514-532 (1953).
- 20

-38-

Second Series of Experiments

Antibodies of the IgA isotype are believed to be the major mediator of the B cell-derived immunity at mucosal sites.

5 Induction of antigen-specific IgA in rectal and genital mucosa can be particularly important in protection against sexually transmitted pathogens, such as the human immunodeficiency virus (HIV-1). For years, investigations have focused primarily on the T-dependent route of B-cell

10 activation that leads to induction of antigen specific IgA. In contrast, little effort has been performed to explore the T-independent route of IgA induction. It has been known for decades that some thymus-independent antigens can induce IgA responses. Recent establishment of a strain of

15 T-cell deficient mice (C57BL, ab/gd T-cell receptor knock-out, -/- mice) provided us a simplified model to investigate the T-independent B-cell responses in vivo in the absence of any T-cell. When a specific microbial polysaccharide, $\alpha(1-6)$ dextran, was injected into these

20 mice, a large number of antigen-specific B-cells, predominately of the IgA isotype, were elicited. The number of antigen specific IgA-secreting cells in spleen was about 30 fold higher than those in normal mice or mice injected with a structurally distinct polysaccharide, B1355S. These

25 findings illustrated clearly the presence of a T-independent (TI) route of IgA induction in living animals and identified a polysaccharide antigen, $\alpha(1-6)$ dextran, as a potent stimulator of IgA-secreting B cells. In this proposal, we plan to investigate: 1) Can $\alpha(1-6)$ dextran

30 serve as a carrier and/or adjuvant to elicit IgA responses to other antigenic determinants? 2) Can $\alpha(1-6)$ dextran-containing conjugates facilitate IgA responses to the gp120 glycoprotein of HIV-1? 3) What are the optimal route(s) of administration of these antigens to

35 elicit antigen specific IgA at mucosal sites? With the

-39-

unique T-independent characteristics, this category of vaccines can be effective not only in normal individuals but also in AIDS patients whose T-cell systems are severely impaired, serving as therapeutic vaccinations against HIV.

5 The principle may also be applied to develop vaccines against opportunistic infections that occur frequently in AIDS patients and in other T-cell deficient syndromes.

10 1. Specific Aims

Our long-term goal is to understand mechanisms of host recognition and antibody responses to microbial antigens and to develop vaccines against infectious diseases. In
15 this study, we take advantage of a simplified model system, the immune response of T cell deficient mice to microbial polysaccharide $\alpha(1-6)$ dextran, to study the T-independent routes of B-cell activation that leads to induction of antigen specific IgA and to explore it for the development
20 of an alternative vaccination strategy against HIV-1. Our specific aims are:

Aim 1. To determine whether $\alpha(1-6)$ dextran can serve as a carrier and/or an adjuvant to elicit IgA responses to
25 other antigenic determinants.

Aim 2. To develop a novel category of TI-conjugates applying $\alpha(1-6)$ dextran to facilitate IgA responses to the gp120 glycoprotein of HIV-1.

Aim 3. To investigate the optimal route(s) of
30 administration of these TI-conjugates to elicit antigen specific IgA at mucosal sites.

Aim 4 To characterize the specificities and HIV-1 neutralization efficiency of IgA antibodies elicited by the T-independent route of immunization.

35

-40-

2. Background and Significance

Mucosal surfaces are protected against infectious microorganisms by the mucosal immune system, of which secretory IgA (s-IgA) is the major humoral defending factor (1, 2). s-IgA is polymeric and is structurally suitable for trapping and clearance of microorganisms in mucosal secretions. A receptor-mediated mechanism effectively transports s-IgA across epithelium to secretions. In the human, the amount of s-IgA exported onto mucosal surfaces can be more than 3 gm per day, far exceeding the amounts of IgG produced for circulation (1, 3, 4). They are frequently reactive with microorganisms in the local mucosal microenvironment, regulating the equilibrium between the host and their resident microorganisms (5, 6). The presence in mucosal secretions of s-IgA specific for microbial antigens highlights the feasibility of developing vaccines directed toward enhancement of mucosal IgA responses.

Natural infection by HIV-1, however, does not elicit a protective IgA response to HIV-1. Many factors may be responsible. These include the intracellular transmission characteristics of the retrovirus (7, 8), masking of the neutralization epitopes of the envelope glycoprotein (gp120) by glycosylation or by other structural elements (9-11), rapid turn-over dynamics of viral replication (12, 13) and the high mutation rates of their RNA genome (12, 14, 15). In addition to these intrinsic properties of the retrovirus, the immune deficiency they induced in AIDS patients further hampers the host responses to the virus. Owing to the specific mechanisms of viral entry, i.e., the specific molecular interactions of gp120 with CD4 and chemokine receptors, T-cell depletion takes place selectively and continuously in AIDS patients. Their

-41-

cellular and humoral immunity, including the mucosal IgA responses to HIV-1 and other pathogens, are seriously impaired. As a consequence of the T-deficient characteristics of the disease, opportunistic infections typically cause death in humans with the disease. Thus, a paradox is created by the retroviral infection: effective vaccinations require functions of T-cells which, however, are irreversibly destroyed by the viral infection.

Are there alternative routes of IgA induction under T cell compromised conditions? It has been known for some time that some thymus-independent antigens (16), such as microbial polysaccharide $\alpha(1-6)$ dextran, can induce antigen specific IgM and IgA antibodies in normal and nude (-/-) mice (17-19). Recognition of a T-cell independent route of IgA induction in vivo was only established recently with studies on the gene-knock out mice that are free of T-cells. This strain was produced by knocking-out both gd and ab T cell receptors (TCR) (20). Unlike nude (-/-) mice, whose thymus-independent, gut-associated T cell system remains intact (21, 22), these KO mice are completely free of T cells (20). Interestingly, immunohistology revealed the presence of IgA producing B cells in the gut and found no germinal center in their lymphoid tissues (20). Thus, in the absence of functional T cells and germinal center, class switching of IgM to IgA took place in these KO mice. When they were challenged with Rotavirus, a reduced yet significant number of IgA-secreting B cells were elicited in the gut, contributing significantly to an effective protection from the gastroenteric pathogen (23). These IgAs were found to be directed exclusively to a viral structural protein, VP6, that forms a repetitive structure in the rotaviral particle. IgA specific for another viral surface protein, VP4, was not detected in KO mice, although IgA specific for both VP6- and VP4 were seen in normal

-42-

C57BL/6 mice. Thus, although T-cells play important roles in the mucosal IgA responses to protein antigens, they are not necessary for the induction of IgA specific for VP6 protein, indicating the involvement of an alternative route of IgA induction that is completely independent of T lymphocytes and their specific cytokines. The importance of structural characteristics of stimulating antigens in IgA induction is implicated by these studies.

The notion of T-independent routes of IgA induction was further established by our recent investigations of B cell responses to microbial polysaccharides in T cell-deficient mice. The strain of KO mice (gd/ab TCR, -/-) in a C57BL background has recently become available from Jackson Laboratories. When native $\alpha(1-6)$ dextran N279 was injected into these mice, a large number of $\alpha(1-6)$ dextran-specific B-cells, predominately of the IgA isotype, were elicited. The number of antigen specific IgA-secreting cells in the spleen was about 30 fold higher than those in C57BL/6J mice immunized by the same antigen. The levels of anti- $\alpha(1-6)$ dextran IgA in serum and in gut mucosal secretions were also markedly elevated in the KO mice as compared with normal C57BL immunized with the same antigen. To see if induction of IgA in the absence of T cells is a common characteristics of TI-antigens, we introduced an additional TI-antigen, $\alpha(1-3)\alpha(1-6)$ dextran (B1355S) in our studies. Unlike $\alpha(1-6)$ dextran, this TI-antigen was unable to elicit antigen-specific IgA in either the T cell-free mice or normal C57BL controls. Thus, some but not all microbial polysaccharides can induce the T-independent route of IgA induction: $\alpha(1-6)$ dextran but not $\alpha(1-3)\alpha(1-6)$ dextran (B1355S) is identified as a potent stimulator of IgA-response. The pathway of B cell activation and differentiation triggered by $\alpha(1-6)$ dextran is completely T-cell independent.

-43-

The structure of $\alpha(1-6)$ dextran has been well characterized. Native dextran N279 is a near-linear macromolecule of glucose with 90% $\alpha(1-6)$, 5% $\alpha(1-)$ and 5% $\alpha(1-3)$ linkages (24) derived from *Leuconostoc mesenteroides*, strain NRRL B512. The predominant $\alpha(1-6)$ glycosidic linkages make it uniquely flexible. Differing from other glycosidic bonds, three torsion(rotational) angles, ϕ , ψ and ω are required to define the conformation of an $\alpha(1-6)$ linkage (17). It is also very stable in vivo, since no mammalian enzyme can digest the linkage. After injection, the polysaccharide was found to be trapped and persist in the splenic follicles, leading to the formation of antigen specific germinal centers (18). $\alpha(1-6)$ dextran is recently identified as a natural ligand of the mannose receptor, which is expressed by follicular dendritic cells and some macrophages (25), providing a possible explanation of selective tissue localization of the polysaccharide. In humans, $\alpha(1-6)$ dextran of relatively smaller molecular weight has been safely applied as blood expander for many years (26). $\alpha(1-6)$ dextran can also be used during surgery as a prophylactic agent to prevent deep venous thrombosis, since the mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) can be inhibited by $\alpha(1-6)$ dextran (27). Thus, there is little safety concern if $\alpha(1-6)$ dextran is used for human vaccination.

In summary, accumulating evidence indicates the presence in vivo of a T-independent route of IgA induction in addition to the conventional T-dependent pathway of IgA responses. Our recent studies of B cell responses to microbial polysaccharides in T cell deficient mice identified a specific microbial polysaccharide, $\alpha(1-6)$ dextran (N279), as a potent IgA activator. It acts in the presence and absence of functional T cells. We hypothesize: 1) An intrinsic structural property of $\alpha(1-6)$ dextran, the most flexible

-44-

5 $\alpha(1-6)$ glycosidic linkage that renders it superior in presenting multiple antigenic determinants for B cell cross-linking activation, is necessary but not sufficient for IgA induction. 2) Its selective cellular and tissue localization, mediated by mannose receptor and/or via other mechanisms, may lead to induction of an unique cytokine profile, contributing significantly to the microenvironment necessary for the activation of B cell-class switch to IgA. We propose, therefore, that $\alpha(1-6)$ dextran of proper molecular weight can serve as a carrier to present other antigenic determinants, such as those derived from the envelope protein(gp120) of HIV-1, to induce IgA responses against HIV-1. Preliminary studies supporting this proposal are summarized in the next section.

15

3. Progress Report

As described below and in a recent review article (17), this study extends in a new direction of previous research on the structure and specificity of antibody combining-sites.

20

Direct evidence demonstrating the existence of T-independent routes of IgA induction

25

As described above, studies using nude(-/-) mice did not completely clarify whether the T-cell plays any role in the TI-responses. A strain of genetically manipulated T cell-free mice was thus introduced. By crossing TCR-b mutant mice with TCR-d mutant mice, TCR-bXd double mutant mice were generated, resulting in the first strain of T-cell-free mice in a mixed (129X C57BL/6) background (20). This strain was back-crossed further to C57BL/6, forming almost a congenic strain of T cell-free mice of C57BL/6 (Peter Mombaerts, personal communication).

35

-45-

These mice and normal controls were immunized with two classical T-independent polysaccharides, $\alpha(1-6)$ dextran (N279) and $\alpha(1-3)\alpha(1-6)$ dextran (B1355S). As shown in Fig.1, a large number of $\alpha(1-6)$ dextran-specific B-cells, predominately of the IgA isotype, were elicited in the KO mice. The number of antigen specific IgA-secreting cells in the spleen is about 30 fold higher than those in C57BL/6J mice. These findings illustrated clearly the presence of a T-independent (TI) route of IgA induction in living animal, providing a simplified model to investigate the underlying cellular and molecular mechanisms (Aim 1).

Structural properties of the stimulating antigen are critical for induction of IgA

As shown in Fig.2. top portion, a structurally distinct polysaccharide, $\alpha(1-3)\alpha(1-6)$ dextran, B1355S, did not elicit an IgA response in either KO or normal C57BL mice. There are at least two explanations for the distinct responses to the two dextrans: 1) The intrinsic reactivity of the responding B cells is the determining factor for their class switching. In fact, antibody responses of both Balb/c (28) and C57BL (29) to B1355S have been shown to be highly restricted in IgM isotype. In contrast, the two strains produce anti- $\alpha(1-6)$ dextrans of both IgM and IgA isotypes (17-19, 30); and 2) The microenvironment is responsible for the induction of IgA-B cells. It has been shown previously that the two dextrans have distinct pattern of cellular compartment localization (17). After administration, $\alpha(1-6)$ dextran was retained in splenic germinal centers and marginal zone in normal mice; $\alpha(1-3)\alpha(1-6)$ dextran was only detectable in splenic marginal zones, but not in follicles. Thus, B cells meet and respond to the two dextrans in different microenvironments.

35

-46-

Co-stimulation with $\alpha(1-6)$ dextran, the B1355S-specific IgA response was extensively enhanced in the KO mice.

5 B cells of different lineage-origins, i.e., B-1 and conventional B cells, may have their unique properties (31, 32). B-cell responses to B1355S were found to be restricted to the B-1 cell population, as illustrated by Förster et al in Balb/c (33); whereas both B-1 and
10 conventional B cells participated in the primary responses to $\alpha(1-6)$ dextran as demonstrated by our studies (34). If the lack of an IgA response to $\alpha(1-3)\alpha(1-6)$ dextran is the intrinsic property of responding B cell, co-administration of $\alpha(1-6)$ dextran may not be able to change the isotype profile of anti- $\alpha(1-3)\alpha(1-6)$ dextran. The KO mice and C57BL
15 normal controls were immunized by i.v. injection of 10 mg polysaccharide B1355S each mouse or with 10 mg each of B1355S and $\alpha(1-6)$ dextran (Mix-Ags). At day 5 post-immunization, antigen-specific ELISAspot assay were performed as described above (Legend for Fig. 1). In
20 contrast to $\alpha(1-6)$ dextran, B1355S alone is not able to elicit IgA response in both KO and normal C57BL mice. Co-injection with $\alpha(1-6)$ dextran, however, led to the induction of significant amounts of IgA secreting cells specific for B1355S in KO mice and to much less extent in
25 C57BL (Fig.2 bottom). Thus, $\alpha(1-6)$ dextran, but not $\alpha(1-6)\alpha(1-6)$ dextran, may activate certain cells in spleen in the absence of T-cells and lead to establishment of a cytokine profile which are necessary for B-cell class
30 switching to IgA.

Taken together, these results are consistent with previous observation applying the T-cell KO mice of mix background(129XC57BL/6J). The presence of a T-independent
35 route of IgA induction in living animal was clearly

-47-

demonstrated, providing a simple model to investigate the underlying mechanisms. The co-immunization experiments (Fig.2) illustrated further that as a potent IgA activator, $\alpha(1-6)$ dextran can enhance the IgA response to a structurally distinct microbial antigen (Fig.2) and influence its antibody light chain repertoire (data not shown). The application potential of $\alpha(1-6)$ dextran in vaccine development is thus highlighted by these studies.

10 Research Design & Methods

These studies will focus on the following specific questions: 1) Can $\alpha(1-6)$ dextran serve as a carrier and/or adjuvant to elicit IgA responses to other antigenic determinants? 2) Can $\alpha(1-6)$ dextran-containing conjugates facilitate IgA responses to the gp120 glycoprotein of HIV-1? 3) What is the optimal route(s) of administration of these TI-conjugates for the induction of mucosal IgA? and 4) Can IgA antibodies elicited by these TI-conjugates neutralize a broad range of HIV-1 strains and what epitope-binding specificities can be responsible for the viral neutralization?

25 Aim 1: $\alpha(1-6)$ dextran as a carrier and/or adjuvant to elicit IgA responses

To trigger the onset of an immune response, a TI antigen must bind and cross-link several antigen receptors on the surface of the B-cells. The number of epitopes carried by a polymer is directly associated with its molecular weight (MW). The nature of the backbone structure of polysaccharides, including residues and glycosidic linkage composition, influence further their interaction with B cells(16, 17). How MW of $\alpha(1-6)$ dextran influences induction of IgA specific for a hapten carried by $\alpha(1-6)$ dextran is

-48-

examined. Also investigated are the optimal conditions for the use of $\alpha(1-6)$ dextran as an adjuvant.

- 5 a) Optimal MWs of $\alpha(1-6)$ dextran-fluorescent(DEX-FITC) conjugates for induction of anti-fluorescent antibodies of IgA isotype

10 To test whether $\alpha(1-6)$ dextran can serve as a carrier to present a small hapten for induction of IgA of a desired specificity and to identify the optimal MWs of the carrier for this purpose, $\alpha(1-6)$ dextran-fluorescent(DEX-FITC) conjugates are tested in both TCR-KO and C57BL mice. The DEX-FITC conjugates of different molecular weights, ranging from 4KD to 2000KD, are commercially available (Sigma). As
15 reported by Fernandez and Möller (35), a preparation of DEX-FITC made from native $\alpha(1-6)$ dextran with a mixture of molecules of different M.W. is immunogenic in mice (35). Antibodies specific either for $\alpha(1-6)$ dextran or for FITC were elicited. The IgA responses to the conjugate was not
20 investigated in the report. It is expected that the conjugates within certain M.W. ranges can be immunogenic in the TCR-KO mice. Thus, i.v. administration of DEX-FITC in these mice allows identification of the optimal M.W. of the carrier for the induction of anti-FITC responses.

25 Mice are immunized by i.v. injection of 10 mg of each antigen, 5-10 mice per group. The number of antigen specific antibody-secreting cells, including IgM, IgA, IgG, and Kappa or Lambda, will be determined at Day 5 by
30 ELISAspot Assay as described (18). Briefly, 96-well microtiter plates are coated with $\alpha(1-6)$ dextran N279 at 10 mg/ml or with Ficoll-FITC. Bound antibodies are revealed with alkaline phosphatase-conjugated antibodies specific for murine antibodies of above different isotypes.
35 Antibodies in serum and in gut secretions will be monitored

-49-

by ELISA assays as described (36, 37). The optimal M.W. of the carrier for the induction of anti-FITC antibodies of the IgA isotype may differ from those for the anti- $\alpha(1-6)$ dextran specificity. This information is of importance to produce the TI-conjugates against HIV-1.

b) $\alpha(1-6)$ dextran as an IgA-adjuvant, its optimal MWs and concentration

As illustrated by the co-immunization experiments (Fig.2), a mixed preparation of native $\alpha(1-6)$ dextran, N279, showed a strong "adjuvant" effect on the IgA response to a co-administrated polysaccharide, $\alpha(1-3)\alpha(1-6)$ dextran. Investigated here are the optimal M.W. and concentration of $\alpha(1-6)$ dextran for its "adjuvant"-effect on the activation of IgA-B cells to the co-antigen, $\alpha(1-3)\alpha(1-6)$ dextran. It is hypothesized that the adjuvant effect of $\alpha(1-6)$ dextran can be attributed to its ability to bind and stimulate some antigen presenting cells, such as dendritic cells and some macrophages expressing the mannose receptor. These events will lead to production of certain non-T cell cytokines, including TGF- β which is critical for IgA induction.

Given this hypothesis, it is predicted that the optimal M.W. of $\alpha(1-6)$ dextran for eliciting anti-dextran antibodies may differ from those required for its adjuvant effect. If the specific binding of $\alpha(1-6)$ dextran by the mannose receptor is critical for the adjuvant effect, the lower M.W. preparation of the molecule shall be sufficient. $\alpha(1-6)$ dextran with M.W. lower than 90KD is not immunogenic (38) yet retain its specific binding by mannose receptor (25, 27). Since such preparations can be safely applied in the human in large dosage without side effect, the effective adjuvant with the lowest M.W. will be identified.

-50-

Aim 2. $\alpha(1-6)$ dextran as a carrier molecule for the generation of the T-independent conjugate-vaccines against HIV-1

5 The optimal M.W. of $\alpha(1-6)$ dextran as identified above is used to produce the TI-conjugates for HIV-1 vaccination. These conjugates may be "completely T-independent", such as the DEX-FITC conjugate; or could be "semi-T-independent" as
10 when a protein or a peptide is coupled to the polysaccharide. The latter may function like a T-independent antigen in the initial stimulation of immune cells but show the T-dependent reactivities after the protein or peptide is processed in vivo. Two semi-TI conjugates, DEX-gp120 and Dex-LeY-peptide, will be
15 prepared.

a) DEX-gp120 conjugates Many protein epitopes are conformational and composed of discontinuous amino acid residues. The DEX-gp120 conjugate is designed to present
20 the gp120 in its native configuration and to take the advantage of $\alpha(1-6)$ dextran for IgA induction as well.

The DEX-gp120 conjugate is developed using a deglycosylated form of the wtD protein of gp120(10). The wtD protein of
25 gp120 lacks the V1 and V2 variable loops but binds CD4 and CCR5 with high affinity. IgA antibodies specific for the regions interacting CD4 or CCR5 may specifically block HIV-1 entry. In addition, this molecule has been successfully crystallized as a complex with CD4 and an
30 monoclonal antibody, 17b, and their structure solved at 2.5 Å by Hendrickson's group at Columbia University(9). It is, thus, possible to correlate the HIV-neutralization activity of an antibody to its epitope-binding specificity. To prepare the deglycosylated wtD protein, Dr. Kwong's
35 experimental procedure is followed [(39)and Kwong &

-51-

Hendrickson, personal communication].

5 Conjugation of the gp120 preparation to $\alpha(1-6)$ dextran will follow a procedure established by Dr. J. Mond's group [(40) and Dr. Andrew Lee, personal communication]. Briefly, aminoethyl-carbamylmethyl dextran (AECM-dextran) is prepared to have amino group introduced onto the neutral polysaccharide. The deglycosylated wtD protein of gp120 is then covalently linked through stable thioether bonds to 10 AECM-dextran using a heterologation technique. The protein will be lightly S-acetylthiolated and the dextran be acylated by introduction of iodoacetamido groups. The two components are then mixed in the presence of hydroxylamine which removes the S-acetyl group. The exposed free 15 sulfhydryl reacts in situ with the iodoacetamido groups.

As evidenced by the anti-Ig-dextran conjugates prepared by the group, this method allows better preservation of protein native structure. Picogram quantities of anti-Ig 20 antibodies coupled to $\alpha(1-6)$ dextran can induce profound B cell activation and antibody production (40). The effects of such conjugates on class switching of IgM to IgA, however, was not reported in their publications.

25 The quality of the gp120-dextran conjugates, i.e., their protein conformation and epitope expression, is monitored by ELISA using antibodies specific for various epitopes of gp120 antibodies. These specific reagents are obtainable from the AIDS Research and Reference Reagent Program or be 30 commercially available. For ELISA assay, the conjugates are captured by anti- $\alpha(1-6)$ dextran mAb pre-coated on ELISA plates. The final evaluation of these conjugates will be of the immune responses they elicit.

35 b) Dex-LeY-peptide conjugate This conjugate is

-52-

designed to induce IgA antibodies specific for the exposed carbohydrate molecule attached on the gp120 glycoprotein of HIV-1. Masking of the neutralization epitopes of gp120 by glycosylation represents one of the important mechanisms that HIV-1 escapes from host immune responses. Recently, some unique carbohydrate structures were identified in the gp120 glycoprotein of HIV-1, such as Tn (GalNAc-Ser/Thr) and Lewis Y (Fuc α 1-2Gal β 1-4 (Fuc α 1-3)GlcNAc β 1-3Gal β 1-4Glc β 1-R), raising the possibility of developing vaccines using these structures. These epitopes appear as surface antigens on most primary human breast carcinomas and their metastases (41), being also molecular targets for cancer vaccination(42, 43).

A DEX-LeY-peptide conjugate is made using a peptide(YRYD) that mimics the carbohydrate structure of Lewis Y. The molecular and functional mimicry of the carbohydrate epitope by the peptide(YRYD) was recently established by Dr. Thomas Kieber-Emmons'group(41). When mice were immunized with a proteosome complex of the peptide, HIV-1 neutralization antibodies were elicited in the serum of both C57BL and Balb/c. Whether the proteosome complex elicited IgA responses was not reported(41).

The Lewis Y-mimicking peptide will be coupled to α (1-6)dextran of proper M.W. For coupling with amino-dextran by glutaraldehyde-conjugation(44), a Lys residue is added in the C-terminal of the peptide. The sequences resulted is "YRYDK". The number of the epitopes per carrier molecule can be controlled by varying the molar ratio of carrier : hapten during conjugation. The conformation of the Lewis Y-mimicking epitope in the conjugate can be investigated using anti-Lewis Y monoclonal antibody, BR552, by an ELISA method(See below).

-53-

An ELISA-based method for monitoring the quality of a conjugate

Basically, the conjugates are captured by anti-dextran mAb
5 pre-coated on plate and the coupled antigen revealed by
another specific antibody to the antigen: a. Coat ELISA
plate with monoclonal anti-dextran, 45.21.1(a,k) (30, 45),
at 5mg/ml, in 0.1M NaHCO₃ pH9.6, 37 °C, 2 hours; Wash the
plates using ELISA washing solution(1XPBS, 0.05% Tween20,
10 0.025% NaAzide) and block with the same solution containing
1%; b. Incubate the coated plates with serial dilution of
the conjugate at 37 °C for 2 hours then wash them with
ELISA washing solution; c. Incubate with antibodies
specific for different epitopes of a given protein at 37 °C
15 for 2 hours then wash them with ELISA washing solution; d.
Incubate with a second antibody specific for the isotype of
the anti-protein antibody used above to monitor the
conjugated epitopes; in separate wells, apply an alkali
phosphatase(AP)-labeled anti-dextran, such as 45.21.1-AP,
20 to detect the available epitopes of the carrier.

This method allows for testing whether desired antigenic
determinants are present in a conjugate and if they are in
the native configurations that are recognizable by
25 antibodies of defined specificities. The molar ratio of an
antigen to a carrier in a conjugate by a semi-quantitative
ELISA assay can also be estimated. In previous
experiments, several Gag-DEX conjugates were tested and it
was found that the immunochemical nature of a conjugate as
30 measured by the ELISA assay correlates well with its in
vivo induction of B cell responses.

Aim 3. Route(s) of administration of TI-conjugates for
the induction of IgA

-54-

The route of antigen administration is one of the critical factors influencing the efficacy of a vaccination (2, 46). The mucosal immune response has certain regional nature, i.e., local exposure to an antigen can result in much higher levels of specific secretory IgA in the region of exposure than at distant sites. Recent studies showed further that immunization at a local site may selectively enhance the responses at other particular sites in addition to the original site. For example, when a TD-antigen cholera toxin(CT) was used to immunize mice, the rectal route was found to be able to induce specific IgA responses at both colonic-rectal and vaginal mucosal sites (47, 48). The basis of these phenomena is believed to be the selective homing of IgA-committed B cells to their functional sites, which are regulated by their differential expression of homing receptors, such as $\alpha 4\beta 7$ (49).

In this experiment, TI-conjugates are studied. The nature of their B cell activation differs significantly from those elicited by a TD-antigenic stimulation. Whether the B cells activated by a T-independent antigen gain a mucosal homing phenotype is unknown. It is documented, however, that the spleen plays an important role in the TI-responses to microbial polysaccharides (50, 51). Thus, the systemic route of immunization when the DEX-conjugates are used must not ignored. Both systemic immunization and mucosal local vaccinations are to be studied.

For systemic immunization, normal C57BL and the TCR-KO mice are given a single dosage i.v. injection. For the mucosal vaccination, the colonic-rectal route is taken as described (47). This route was shown to be the best for induction of IgA responses at the colonic-rectal site as well as the vaginal site (47, 48). The dosage and time (kinetics) responses to each conjugate are studied. The B cell

-55-

responses in spleen and gut tissues by tissue section staining and by ELISAspot assay as described (18) are monitored. Specific antibodies in serum and in gut secretions are detected by ELISA assay for their binding to gpl20 and to the carrier molecule. Dr. Marian R. Neutra's wick method is adapted to collect mucosal secretions of the gut(47).

The following questions are specifically addressed:

10

1. Can TI-conjugates induce antigen-specific IgA-B cells in spleen as well as in the gut? The carrier molecule alone has been found to induce s-IgA in gut secretion in the TCR-KO mice (data not shown). These IgA antibodies may be derived from circulation via an active IgA-transporting system in the liver. Alternatively, they may be produced locally by IgA-plasma cells migrated (from spleen) to lamina propria of the gut. It is predicted that the first mechanism certainly contributes to s-IgA in the gut. The second mechanism is, however, not impossible, since i) the homing receptor $\alpha 4\beta 7$ is detectable in the peritoneal B-1 cells (52); ii) B-1 cells contribute to IgA-plasma cells in the gut (5, 6, 53); and iii) both B-1 and conventional B cells are involved in the splenic B cell responses to $\alpha(1-6)$ dextran (34). If the number of antigen-specific IgA-plasma cells in the gut were significantly increased, either by a single i.v.-injection of an antigen or as a consequence of a local mucosal boosting with the antigen, the second possibility, i.e., a TI-antigen-induced B-cell migration and mucosal homing, will be strongly supported. Further studies in this direction will be carried.

20
25
30

2. Can these TI-conjugates elicit IgA-antibodies specific for the expected epitopes of the gpl20 glycoprotein of HIV-1? At this stage, applicants use the glycosylated

35

-56-

native gp120 and the deglycosylated gp120wtD for ELISA to distinguish the specificities for protein-epitope-specificities and those for carbohydrate structures.

5

3. Can they elicit a booster response? As shown in Fig.1 (progress report), the number of IgA-secreting cells in the spleen of normal mice is drastically less than those of IgM-anti-dextran. This isotype profile differs from the previous observation that about equal number of IgA- and IgM-hybridoma were obtained from the mice immunized by $\alpha(1-6)$ dextran(19, 30). One hypothesis is that in the presence of functional T-cells(normal mice), the IgA-committed cells activated in the spleen migrate to the mucosal sites for their terminal differentiation and s-IgA production. In the absence of T-cells(TCR-KO), however, their terminal differentiation may take place in the spleen. To test this possibility, the immunized-mice are challenged via the rectal route of immunization. Both TCR-KO and normal mice are used in the experiments. If a booster-response in the is observed in normal mice but not in TCR-KO mice, this hypothesis will be supported.

25

4. Can these TI-conjugates elicit gp120-specific germinal centers in spleen and gut? Answering this question is important, since many of the critical molecular and cellular events of B cell activation and differentiation take place in the germinal center, including clonal selection and expansion of B memory cells, class switching, somatic hypermutation and affinity maturation. These TI-conjugates may be trapped by follicular dendritic cells via their binding to $\alpha(1-6)$ dextran or by other mechanisms and thus are potentially capable of inducing germinal center reaction in normal mice.

35

-57-

If a gp120-specific IgA response cannot be effectively induced by these conjugates, the search for improvement in two direction is planned : i) Structure of conjugates. An important parameter that may be adjusted further is the molecular weight of the final product. The optimal molecular weights chosen for conjugation is based on a study in Aim1 using DEX-FITC as a model. Since FITC is a small hapten, the carrier M.W. required for DEX-FITC may differ from those for DEX-gp120 or DEX-LeY; ii) Different vaccination strategies. For example, mice may be primed with a TD-conjugate to initiate a B cell response and then boost them using above TI-conjugate. In AIDS patients, the antibody response to HIV protein was already initiated by the infection. Vaccination with the TI-conjugates for them may be sufficient to induce an IgA-response. Thus, boosting with TI-conjugates may be an important addition to HIV-therapeutic vaccinations.

Aim 4. HIV neutralization activity and binding specificities of IgA antibodies

a) Neutralization of HIV. It is of critical importance to test whether the IgA-antibodies induced by above TI-conjugates can neutralize various strains of HIV-1. Sera and gut secretions can be sufficient for an initial testing; a detailed characterization will be done using monoclonal antibodies(see below). Samples collected from immunized mice are compared with those from non-immunized animals.

The HIV neutralization assay is performed as described (41). Briefly, Cell-free HIV-1/MN and HIV-1/3B, obtainable from the AIDS Research and Reference Reagent Program, will be propagated in H9 cells. One hundred TCID50 of virus free of cells are pre-incubated with serial dilution of

-58-

experimental samples for 1 hour at 37 °C. The pretreated virus is then plated on target cells, for 1h. Neutralization is detected as inhibition of syncytia 3 days later, assessed by counting the number of multinuclear cells. The neutralization activities using clinical isolates of HIV-1 will be tested further.

b) Monoclonal antibodies with interesting specificities for gp120 Several reasons make it necessary to establish specific monoclonal antibodies in this proposal:

1) To correlate the neutralization activity of an antibody to its epitope-binding specificity. As described above, the structures of gp120wtD and its complex with CD4 and mAb 17b have been solved. A series of mutant clones of gp120 are also available, allowing detailed analysis of antibody binding specificities for the protein. Although a panel of monoclonal antibodies of defined anti-gp120 specificities have been established (11), it is of interest to obtain mAb recognizing other conserved, neutralization epitopes of gp120, including particularly those specific for the carbohydrate structure attached to gp120 glycoprotein. Since here a distinct strategy is developed, i.e., the TI-route of IgA induction, monoclonal antibodies of unique specificities may be obtained. There is much evidence that antibodies recognizing the exposed carbohydrate structures of microorganisms are frequently protective against infection by corresponding pathogens (2, 17). Such specificities can be especially important for protection against HIV-1 by mucosal IgA.

2) To test whether anti-gp120 mAbs of IgA isotype are better than other antibody isotypes for HIV-1 neutralization and what kind of epitope-binding specificities can be better associated with the

-59-

IgA-mediated neutralization activities. Monoclonal antibodies with same V-region but different H-chain isotypes, either IgA or IgG, are required for these studies.

5

3) To see whether our immunization strategy using TI-conjugates can induce IgA- antibodies of higher affinities and if somatic mutation occurs during the TI-route of IgA induction. For these purposes, immunochemical mapping and molecular characterization of antibody combining-site of monoclonal antibodies are necessary.

15

It is expected that hybridomas will be established in this project period. In fact, applicants must do so when a specific IgA response is monitored in a vaccination. Hybridoma techniques were applied in previous studies to obtain mAbs to dextrans and to other antigens (19, 30). These techniques are applied to obtain monoclonal antibodies with interesting specificities to the gp120 glycoprotein of HIV-1. To investigate the above questions monoclonal antibodies are to be used.

20

In summary, $\alpha(1-6)$ dextran, a newly discovered IgA-activator, is used as a carrier to present distinct antigenic determinants of the gp120 glycoprotein of HIV-1. Two T-independent conjugates, DEX-gp120wtD and DEX-LeY-peptide, are produced and their efficacy in eliciting IgA-responses to HIV-1 investigated. Both T-cell deficient mice and normal C57BL are applied to study the immunological activities of these conjugates. Important information regarding vaccine development using $\alpha(1-6)$ dextran is provided. These studies, if successful, are extended to human vaccination against HIV-1.

30

35

References for the Second Series of Experiments

1. Mestecky, J., and J. R. McGhee. 1987. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. [Review]. Advances in Immunology 40:153-245.
2. Kraehenbuhl, J. P., and M. R. Neutra. 1992. Molecular and cellular basis of immune protection of mucosal surfaces. Physiological Rev. 72:853-879.
3. Seilles, E., D. Vuitton, P. Sava, P. Claude, J. Panouse, A. Roche, and D. L. Delacroix. 1985. IgA and its different molecular forms in the mesenteric, portal and peripheral venous blood in man. Gastroenterol. Clin. Biol. 9:607-613.
4. Mestecky, J., C. Lue, and M. W. Russell. 1991. Selective transport of IgA: cellular and molecular aspects. Gastroenterol. Clin. North. Am. 20:441-471.
5. Bos, N. A., J. C. Bun, S. H. Popma, E. R. Cebra, G. J. Deenen, M. J. van der Cammen, F. G. Kroese, and J. J. Cebra. 1996. Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria. Infection & Immunity 64:616-23.
6. Bos, N. A., J. C. Bun, H. Bijma, E. R. Cebra, J. J. Cebra, G. J. Deenen, M. J. van der Cammen, and F. G. Kroese. 1994. Analysis of IgA-producing hybridomas derived from peritoneal B1 cells. Advances in Experimental Medicine & Biology 355:265-9.
7. Varmus, H. E. 1983. Retroviruses. In Mobile Genetic

-61-

Elements. J. A. Shapiro, ed. Academic Press, New York, p. 411-501.

- 5 8. Sabin, A. B. 1992. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc. Natl. Acad. Sci. USA 89:8852-8855.
- 10 9. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. Hendrickson. 1998. Structure of an HIVgp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
- 15 10. Rizzuto, C. D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P. D. Kwong, W. Hendrickson, and J. Sodroski. 1998. A conserved HIVgp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
- 20 11. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. Hendrickson, and J. Sodroski. 1998. The antigenic structure of the HIVgp120 envelope glycoprotein. Nature 393:705-711.
- 25 12. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Eminl, P. Deutsh, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
- 30 13. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
- 35

-62-

14. Campbell, B. J., and V. M. Hirsch. 1994. Extensive envelope heterogeneity of simian immunodeficiency virus in tissues from infected macaques. *J. Virol.* 68:3129-3137.
- 5
15. Hirsch, V. M., J. E. Martin, G. Dapolito, W. R. Elkins, W. T. London, S. Goldstein, and P. R. Johnson. 1994. Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus. *J. Virol.* 68:2649-2661.
- 10
16. Mond, J. J., A. Lees, and C. M. Snapper. 1995. T cell-independent antigens type 2. In *Annual Review of Immunology*, vol. 13, p. 655-92.
- 15
17. Wang, D., and E. A. Kabat. 1996. Carbohydrate Antigens(Polysaccharides). In *Structure of Antigens*, vol. Three. M. H. V. V. Regenmortal, ed. CRC Press, Boca Raton New York London Tokyo, 1996., p. 247-276.
- 20
18. Wang, D., S. M. Wells, A. M. Stall, and E. A. Kabat. 1994. Reaction of germinal centers in the T-independent response to the bacterial polysaccharide $\alpha(1-6)$ dextran. *Proc. Natl. Acad. Sci. USA* 91:2504-2506.
- 25
19. Wang, D., J. Liao, D. Mitra, P. N. Akolkar, F. Gruezo, and E. A. Kabat. 1991. The repertoire of antibodies to a single antigenic determinant. *Mol. Immunol.* 28:1387-1397.
- 30
20. Mombaerts, P., E. Mizoguchi, H. G. Ljunggren, J. Iacomini, H. Ishikawa, L. Wang, M. J. Grusby, L. H. Glimcher, H. J. Winn, A. K. Bhan, and S. Tonegawa. 1994. Peripheral lymphoid development and function in
- 35

-63-

T cell receptor mutant mice. Int. Immunol.
6:1061-1070.

21. Poussier, P., P. Edouard, C. Lee, M. Binnie, and M.
5 Julius. 1992. Thymus-independent development and
negative selection of T cells expressing T cell
receptor α/β in the intestinal epithelium: evidence
for distinct circulation patterns of gut- and
thymus-derived T lymphocytes. J. Exp. Med.
10 176:187-199.
22. Saito, H., Y. Kanamori, T. Takemori, H. Nariuchi, E.
Kubota, H. Takahashi-Iwanaga, T. Iwanaga, and H.
Ishikawa. 1998. Generation of intestinal T cells from
15 progenitors residing in gut cryptopatches. Science
280:275-278.
23. Franco, M. A., and H. B. Greenberg. 1997. Immunity to
rotavirus in T cell deficient mice. Virology
20 238:169-179.
24. Jeanes, A. 1986. Immunochemical and related
interactions with dextrans reviewed in terms of
improved structural information. Mol. Immunol.
25 23:999-1028.
25. Sallusto, F., M. Cella, C. Danieli, and A.
Lanzavecchia. 1995. Dendritic cells use
macropinocytosis and the mannose receptor to
30 concentrate macromolecules in the major
histocompatibility complex class II compartment:
downregulation by cytokines and bacterial products
[see comments]. J Exp Med 182:389-400.
- 35 26. Kabat, E. A., and D. Berg. 1953. Dextran--an antigen

-64-

in man. J.Immunol. 70:514-532.

- 5 27. Noorman, F., M. M. Barrett-Bergshoeff, M. Bekkers, J. J. Emeis, and D. C. Rijken. 1997. Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effect. Thromb Haemost 78:1249-54.
- 10 28. Schuler, W., A. Schuler, and E. Kolsch. 1984. Immune response against the T-independent antigen alpha (1----3) dextran. II. Occurrence of B gamma memory cells in the course of immunization with the native polysaccharide is T cell dependent. European Journal of Immunology 14:578-85.
- 15 29. Tittle, T. V. 1989. Immunochemical analyses of C57BL/6J monoclonal anti- α (1-3) Dextran antibodies. Mol. Immunol. 26:343-350.
- 20 30. Wang, D., H. Chen, J. Liao, P. N. Akolkar, S. K. Sikder, F. Gruezo, and E. A. Kabat. 1990. Two families of monoclonal antibodies to α (1-3)dextran, VH19.1.2 and VH9.14.7, show distinct patterns of Jk and JH minigene usage and amino acid substitutions in CDR3. J. Immunol. 145:3002-3010.
- 25 31. Herzenberg, L. A., A. M. Stall, P. A. Lalor, C. Sidman, W. A. Moore, D. R. Parks, and L. A. Herzenberg. 1986. The Ly-1 B cell lineage. Immunological Reviews 93:81-102.
- 30 32. Herzenberg, L. A., and A. B. Kantor. 1993. B-cell lineages exist in the mouse. [Review]. Immunology Today 14:79-83.
- 35

-65-

33. Förster, I., and K. Rajewsky. 1987. Expansion and functional activity of Ly-1+ B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice. *Eur. J. Immunol.* 17:521-528.
- 5
34. Wells, S. M., D. Wang, E. A. Kabat, and A. M. Stall. 1998. Involvement of B-1 and Conventional B Cell Populations in the T-independent Response to $\alpha(1\rightarrow6)$ dextran. *J. Immunol.*:Submitted.
- 10
35. Fernandez, C., and G. Moller. 1979. A thymus-independent IgG response against dextran B512 can be induced in C57BL but not in CBA mice, even though both strains possess a VHdex gene. *Scand J Immunol* 10:465-72.
- 15
36. Chen, H. T., S. D. Makover, and E. A. Kabat. 1987. Immunochemical studies on monoclonal antibodies to stearyl-isomaltotetraose from C58/J and a C57BL/10 nude mouse. *Mol. Immunol.* 24:333-338.
- 20
37. Matsuda, T., and E. A. Kabat. 1989. Variable region cDNA sequences and antigen binding specificity of mouse monoclonal antibodies to isomaltosyl oligosaccharides coupled to proteins T-dependent analogues of $\alpha(1\rightarrow6)$ dextran. *J. Immunol.* 142:863-870.
- 25
38. Kabat, E. A., and A. E. Bezer. 1958. The effect of variation in molecular weight on the antigenicity of dextran in man. *Arch. Biochem. Biophys.* 78:306-318.
- 30
39. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. Hendrickson. 1998. Quantitative probability analysis and variational crystalization of gp120, the exterior envelope glycoprotein of the human
- 35

-66-

immunodeficiency virus type 1 (HIV-1). J. Biol. Chem.
(submitted).

- 5 40. Brunswick, M., F. Finkelman, P. F. Highet, J. K.
Inman, H. M. Dintzis, and J. J. Mond. 1988. Picogram
quantities of anti-Ig antibodies coupled to dextran
induce B cell proliferation. J. Immunol. 140:3364.
- 10 41. Agadjanyan, M., P. Luo, M. A. Westerink, L. A. Carey,
W. Hutchins, Z. Steplewski, D. B. Weiner, and T.
Kieber-Emmons. 1997. Peptide mimicry of carbohydrate
epitopes on human immunodeficiency virus [see
comments]. Nat Biotechnol 15:547-51.
- 15 42. Springer, G. F., P. R. Desai, W. Wise, S. C.
Carlstedt, R. Stein, H. Tegtmeier, and E. F. Scanlon.
1990. Pancarcinoma T and Tn epitopes: autoimmunogens
and diagnostic markers that reveal incipient
carcinomas and help establish prognosis. In
20 Immunodiagnosis of Cancer. R. Herberman, and D.
Mercer, eds. Marcel Dekker, New York, p. 587-612.
- 25 43. Barr, N., C. R. Taylor, T. Young, and G. F. Springer.
1989. Are pancarcinoma T and Tn differentiation
antigens? (published erratum corrected in Cancer 1989
Oct 15;64(8):1594.). Cancer 64:834-841.
- 30 44. Avrameas, S. 1969. Coupling of enzyme to proteins with
glutaraldehyde. Immunochemistry 6:42-52.
- 35 45. Sharon, J., E. A. Kabat, and S. M. Morrison. 1982.
Immunochemical characterization of binding sites of
hybridoma antibodies specific for a(1->6)linked
dextran. Mol. Immunol. 19:375.

-67-

46. Mestecky, J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. [Review]. *Journal of Clinical Immunology* 7:265-76.
- 5
47. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J. P. Kraehenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. *Infect Immun* 62:15-23.
- 10
48. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, and M. R. Neutra. 1995. The colon and rectum as inductor sites for local and distant mucosal immunity. *Adv Exp Med Biol* 371A:107-109.
- 15
49. Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. *Science* 272:60-6.
- 20
50. Van den Eertwegh, A. J. M., J. Laman, D., M. M. Schellekens, W. J. A. Boersma, and E. Claassen. 1992. Complement-mediated follicular localization of T-independent type-2 antigens: the role of marginal zone macrophages revisited. *Eur. J. Immunol.* 22:719-726.
- 25
51. Timens, W., A. Boes, T. Rozeboom-Uiterwijk, and S. Poppema. 1989. Immaturity of the human splenic marginal zone in infancy: possible contribution to the deficient infant immune response. *J. Immunol.* 143:3200-3206.
- 30
52. Donze, H. H., C. Lue, B. A. Julian, W. H. Kutteh, A. Kantele, and J. Mestecky. 1997. Human peritoneal B-1
- 35

-68-

cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels. Clin Exp Immunol 109:356-61.

5

53. Kroese, F. G., J. J. Cebra, J. F. van der Cammen, A. B. Kantor, and N. A. Bos. 1995. Contribution of B1 cells to intestinal IgA production in the mouse. Methods 8:37-43.

10

What is claimed is:

- 5 1. A method of identifying an $\alpha(1,6)$ dextran molecule
as a potent IgA-B cell activator comprising the
steps of:
- 10 (a) conjugating a first and a second $\alpha(1,6)$
dextran molecule, each molecule having a
different molecular weight of ≥ 90 kd, to an
HIV-1 gp120 glycoprotein, an HIV-1 protein
or epitopes thereof to produce a T-
independent $\alpha(1,6)$ dextran conjugate;
- 15 (b) administering the first T-independent $\alpha(1,6)$
dextran conjugate produced in step (a) to a
subject to induce anti-HIV-1 gp120
antibodies in the subject;
- 20 (c) detecting an amount of anti-HIV-1 gp120
antibodies induced in step (b) in the
subject;
- (d) administering the second T-independent
 $\alpha(1,6)$ dextran conjugate produced in step
(a) to a subject to induce anti-HIV-1 gp120
antibodies in the subject;
- 25 (e) detecting an amount of anti-HIV-1 gp120
antibodies induced in step (d) in the
subject;
- (f) comparing the amount of anti-HIV-1 gp120
antibodies detected in step (c) to the
amount of anti-HIV-1 gp120 antibodies
detected in step (e), wherein detection of a
greater amount of anti-HIV-1 gp120
antibodies induced by the first or second
5 $\alpha(1,6)$ dextran molecule identifies the
 $\alpha(1,6)$ dextran molecule which is a potent

-70-

IgA-B cell activator.

2. The method of claim 1, wherein the induced anti-HIV-1 gp120 antibodies are IgA antibodies or IgG antibodies.
5
3. The method of claim 1, wherein the HIV-1 gp120 glycoprotein is a deglycosylated wildtype HIV-1 gp120 glycoprotein or a deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein.
10
4. The method of claim 3, wherein the deglycosylated wildtype HIV-1 gp120 glycoprotein or the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein binds CD4 or an HIV-1 co-receptor.
15
5. The method of claim 4, wherein the HIV-1 co-receptor is HIV-1 coreceptor CCR5.
- 20 6. The method of claim 3, wherein the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein has domains v_1 and v_2 deleted from the deglycosylated wildtype HIV-1 gp120 glycoprotein.
25
7. The method of claim 1, wherein in step (a) the $\alpha(1,6)$ dextran molecule is conjugated to the HIV-1 gp120 glycoprotein or an epitope thereof, by a heterologation technique.
30
8. The method of claim 1, wherein the HIV-1 gp120 glycoprotein epitope is a carbohydrate epitope.
9. The method of claim 8, wherein the carbohydrate epitope is coupled to a lipid carrier and
35

SUBSTITUTE SHEET (RULE 26)

-71-

incorporated into the surface of a liposome carrier.

- 5 10. The method of claim 9, wherein an additional carbohydrate epitope is incorporated into the liposome, wherein the carbohydrate epitope comprises an isomaltosyl oligosaccharide.
- 10 11. The method of claim 10, herein the isomaltosyl oligosaccharide comprises a $[Glc(\alpha(1,6))]_n$ motif.
- 15 12. The method of claim 1, wherein the HIV-1 gp120 protein or an epitope thereof is biotinylated and is conjugated by avidin to the $\alpha(1,6)$ dextran which is biotinylated.
- 20 13. The method of claim 1, wherein the HIV-1 gp120 glycoprotein epitope is Tn (GalNAc-Ser/Thr), Lewis Y ($Fuc\alpha 1 \rightarrow 2Gal\beta 1 \rightarrow 4(Fuc\alpha 1 \rightarrow 3)GlcNAc\beta 1 \rightarrow 3Gal\beta 1 \rightarrow 4Glc\beta 1 \rightarrow R$) or peptide mimics thereof.
- 25 14. The method of claim 1, wherein the HIV-1 gp120 protein is a Gag p55 polyprotein or a capsid p24 protein.
- 30 15. The method of claim 1, wherein the Gag is a Gag-GST fusion protein or a purified Gag protein.
- 35 16. A method of inducing antigen specific antibodies in an immunocompromised subject, wherein the antigen comprises an epitope of HIV-1 gp120 glycoprotein an or an HIV-1 protein, comprising administering an effective amount of a T-independent $\alpha(1,6)$ dextran conjugate to the immunocompromised subject.

-72-

17. The method of claim 16, wherein the antibodies are IgA antibodies or IgG antibodies.
- 5 18. The method of claim 16, wherein the T-independent $\alpha(1,6)$ dextran conjugate comprises an $\alpha(1,6)$ dextran and a protein coupled thereto.
- 10 19. The method of claim 18, wherein the protein is HIV-1 gp120 glycoprotein, deglycosylated wildtype HIV-1 gp120 glycoprotein or the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein.
- 15 20. The method of claim 19, wherein the deletion form of the deglycosylated wildtype HIV-1 gp120 glycoprotein has domains v_1 and v_2 deleted from the deglycosylated wildtype HIV-1 gp120 glycoprotein.
- 20 21. The method of claim 16, wherein the T-independent $\alpha(1,6)$ dextran conjugate comprises gp120, a deletion form of gp120 wildtype, a deglycosylated gp120 or a deletion form of deglycosylated gp120.
- 25 22. The method of claim 16, wherein the T-independent $\alpha(1,6)$ dextran conjugate is DEX-LeY-peptide.
23. The method of claim 16, wherein the epitope of gp120 glycoprotein is a carbohydrate molecule.
- 30 24. The method of claim 23, wherein the carbohydrate molecule is Tn (GalNAc-Ser/Thr).
25. The method of claim 23, wherein the carbohydrate

-73-

molecule is a peptide mimic of a mucin-type structure or of a peripheral poly-N-acetyl-glucosamine carbohydrate structure.

- 5 26. The method of claim 25, wherein the carbohydrate-mimicking peptide is YPY that mimics mannose or WRY that mimics ($\alpha(1 - 4)$ glucose.
- 10 26. The method of claim 23, wherein the carbohydrate molecule is Lewis Y (Fuc α 1 \rightarrow 2Gal β 1 \rightarrow 4 (Fuc α 1 \rightarrow 3)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc β 1 \rightarrow R).
- 15 27. The method of claim 23, wherein the epitope is a peptide mimic of Lewis Y.
28. The method of claim 23, wherein the peptide mimic of Lewis Y comprises the amino acid sequence YYRYD or YYRYDK.
- 20 29. The method of claim 16, wherein the induced antigen specific antibodies are IgA antibodies or IgG antibodies in the circulation of the subject or at mucosal sites of the subject.
- 25 30. The method of claim 29, wherein the induced mucosal IgA antibodies are colo-rectal, genital, or oral IgA antibodies.
- 30 31. The method of claim 16, wherein the immunocompromised subject is infected with human immunodeficiency virus-1 (HIV-1).
32. The method of claim 16, wherein the subject is T-cell deficient.

35

-74-

33. The method of claim 16, wherein the subject is not T-cell deficient.
- 5 34. The method of claim 16, wherein the T-independent $\alpha(1,6)$ dextran conjugate is administered to a mucosal surface of the immunocompromised subject or via a systemic route of vaccination.
- 10 35. The method of claim 34, wherein the administration is topical, oral, nasal, anal, liposome-mediated delivery, aerosol delivery, intravenous delivery or subcutaneous delivery.
- 15 36. A method of enhancing IgA response in an immunocompromised subject comprising administering $\alpha(1,6)$ dextran having a molecular weight of $< 90\text{kd}$ and an effective amount of an antigen concurrently.
- 20 37. The method of claim 36, wherein the subject is T-cell deficient.
38. The method of claim 36, wherein the subject is not T-cell deficient.
- 25 39. The method of claim 36, wherein the antigen comprises an HIV-1 gp120 glycoprotein, or other HIV-1 proteins or epitopes derived from HIV proteins.
- 30 40. The method of claim 39, wherein the HIV-1 gp120 glycoprotein is deglycosylated wildtypeD gp120 protein.
- 35 41. The method of claim 40, wherein the deglycosylated wildtype HIV-1 gp120 glycoprotein is a deletion

-75-

form of the deglycosylated wildtype HIV-1 gp120 glycoprotein having deletions of domains v_1 and v_2 .

- 5 42. The method of claim 39, wherein the HIV-1 gp120 glycoprotein epitope is Tn (GalNAc-Ser/Thr), Lewis Y ($\text{Fuc}\alpha 1 \rightarrow 2\text{Gal}\beta 1 \rightarrow 4 (\text{Fuc}\alpha 1 \rightarrow 3)\text{GlcNAc}\beta 1 \rightarrow 3\text{Gal}\beta 1 \rightarrow 4\text{Glc}\beta 1 \rightarrow \text{R}$) or peptide mimics thereof.
- 10 43. A method of treating an immunocompromised subject comprising the method of claim 16.
44. A method of treating an immunocompromised subject comprising the method of claim 36.
- 15 45. A method of preventing AIDS or HIV-1 infection in a subject comprising the method of claim 16.
46. A method of preventing AIDS or HIV-1 infection in a subject comprising the method of claim 36.
- 20 47. A method of producing a T-independent conjugate comprising conjugating a microbial antigen protein or an epitope thereof to $\alpha(1,6)$ dextran.
- 25 48. The method of claim 47, wherein the microbes are Cytomegalovirus, Mycobacterium avium, or Cryptococcus.
- 30 49. The method of claim 47, wherein the microbial protein antigen or an epitope thereof is conjugated to $\alpha(1,6)$ dextran by a heterologation technique.
- 35 50. A method of inducing antigen specific IgA in a subject, wherein the antigen is a bacterial envelope protein, carbohydrate, or a fragment

-76-

thereof comprising administering a therapeutically effective amount of the T-independent conjugate vaccine produced by the method of claim 47 to the subject.

5

51. A method of inducing antigen specific IgA in a subject, wherein the antigen is a microbial antigen or epitope thereof comprising administering $\alpha(1,6)$ dextran and an effective amount of an antigen sequentially or concurrently.

10

52. The method of either of claim 50 or 51, wherein the subject is T-cell deficient.

15

53. The method of either of claim 50/39 or 51/40, wherein the subject is not T-cell deficient.

54. A method of treating a microbial infection in a subject comprising the method of claim 50.

20

55. The method of either of claim 52 or 53, wherein the microbial infection is an opportunistic infection.

25

56. The method of claim 55, wherein the subject is infected with HIV-1 or has AIDS.

57. A method of treating a microbial infection in a subject comprising the method of claim 51.

30

58. A method of preventing a microbial infection in a subject comprising the method of claim 50.

35

59. A method of preventing a microbial infection in a subject comprising the method of claim 51.

60. The method of any of claims 50, 51, 54, 56, 57, 58

-77-

and 58, wherein the T-independent $\alpha(1,6)$ dextran conjugate is administered to a mucosal surface of the microbial infected subject or via a systemic route of vaccination.

- 5
61. The method of any of claims 50, 51, 54, 56, 57, 58 and 59, wherein the administration is topical, oral, nasal, anal, liposome-mediated delivery, aerosol delivery, intravenous delivery or
- 10 subcutaneous delivery.
62. A composition comprising a T-independent conjugate in an amount effective to induce antigen specific IgA in a subject and a pharmaceutically acceptable
- 15 carrier.
63. A method of producing a composition comprising a T-independent conjugate in an amount effective to induce antigen specific IgA in a subject and a pharmaceutically acceptable carrier comprising the
- 20 method of claim 1 and further comprising admixing the T-independent conjugate and the pharmaceutically acceptable carrier.
- 25 64. A composition comprising an effective amount of a T-independent conjugate and a pharmaceutically acceptable carrier, wherein the T-independent conjugate is produced by the method of claim 1.
- 30 65. A composition comprising a effective amount of a T-independent conjugate and a pharmaceutically acceptable carrier, wherein the T-independent conjugate is produced by the method of claim 47.
- 35 66. Use of the $\alpha(1,6)$ dextran molecule identified as a potent antibody activator in claim 1 as a carrier or an adjuvant for vaccines to enhance

-78-

mucosal immunity.

67. The method of claim 1, wherein the T-independent
conjugate is used as a vaccine to induce antigen
specific IgA.
- 5

1/4

FIG. 1A




FIG. 1B

2/4

FIG. 2A







FIG. 2B

3/4



4/4

FIG.4



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/18750

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) A01N 25/00, 43/04; A61K 49/04

US CL Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9.1, 9.2, 147.1, 148.1, 159.1, 160.1, 193.1, 194.1, 196.1, 208.1, 280.1, 283.1; 514/54, 59, 777

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EHRHARDT et al. Differential Activation Requirements of Isotype-Switched B Cells. European Journal of Immunology. August 1996, Vol.26, No.8, pages 1926-1934, see entire document.	1-67
Y	WANG et al. Reaction of Germinal Centers in the T-Cell-Independent Response to the Bacterial Polysaccharide Alpha(1-->6) Dextran. Proceedings of the National Academy of Sciences of the United States of America. 29 March 1994, Vol.91, No.7, pages 2502-2506, see entire document.	1-67



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents.	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 NOVEMBER 1998

Date of mailing of the international search report

19 NOV 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY STUCKER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/18750

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SNAPPER et al. IgE Class Switching is Critically Dependent Upon the Nature of the B Cell Activator, in Addition to the Presence of IL-4. Journal of Immunology. 15 August 1991, Vol.147, No.4, pages 1163-70, see entire document.	1-67
Y	FERNANDEZ et al. The Influence of T Cells on the Immunoglobulin Repertoire and the Affinity Maturation of the Immune Response Against Dextran B512 in C57BL/6 Mice. Scandinavian Journal of Immunology. March 1991, Vol.33, No.3, pages 307-317, see entire document.	1-67

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/18750

A. CLASSIFICATION OF SUBJECT MATTER:

US CL.

424/9.1, 9.2, 147.1, 148.1, 159.1, 160.1, 193.1, 194.1, 196.1, 208.1, 280.1, 283.1; 514/54, 59, 777